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African Americans are noted as having a low prevalence metabolic syndrome (MetS), 
which is partly attributed to a reported use of MetS criteria, such as waist 
circumference that is not appropriate for this population group. The purpose of this 
study was: 1) to investigate the gender specific optimal waist cut off points, which 
best identify individuals with metabolic abnormalities consistent with MetS, and are 
independent of body mass index (BMI) cutoff values; 2) to determine the gender 
specific cutoff values of BMI in relation to multiple metabolic risk factors; and 3) to 
assess the prevalence of metabolic syndrome. In this cross-sectional study, NHANES 
data from 1999-2006 was analyzed. 1445 participants had complete variables for 
metabolic syndrome criteria. The waist circumference of 95 cm for males and 98 cm 
for females were found as appropriate cut-off values to identify central obesity. Body 
  
mass index at which metabolic syndrome was observed was 28 kg/m² for males and 
32 kg/m² for females. Using our newly estimated waist circumference thresholds, the 
age-adjusted prevalence of MetS was 30.9% in males and 30.3% in females. The 
results indicate that for the early detection of metabolic syndrome in African 
American adult males, a lower cutoff value of 95 cm, rather than the 102 cm currently 
used is needed. The metabolic syndrome abnormalities appear at higher body mass 
index and waist circumference among women.  Based on our findings, the prevalenc  
of metabolic syndrome is currently underestimated among African American adult 
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CHAPTER 1: INTRODUCTION 
The presence of metabolic syndrome is defined as 3 or more of 5 metabolic risk 
factors. The latter include high blood pressure, hyperglycemia, hypertriglyceridemia, 
low high density lipoprotein – cholesterol and large waist circumference (1, 2). Other
factors including microalbuminuria, hyperuricemia, changes in clotting factors, 
chronic inflammation, and fatty liver have received attention in attempt to define the 
syndrome.  It is recognized that the most prevalent form of the clustering 
abnormalities of the metabolic syndrome, linked to insulin resistance, is observed in 
subjects with abdominal obesity, in particular with excess visceral adipose tissu (3, 
4). Abdominal obesity is measured by waist circumference (WC), which is 
considered a better marker of abdominal fat accumulation than the body mass index 
due to a higher correlation with visceral adipose tissue (5). However, there is still 
debate on appropriate population-based WC cutoff points.  
Heterogeneity of abdominal tissue composition, in particular fat mass and skeletal 
mass, and its association with metabolic risk factors in different ethnic groups does 
not allow a universal WC cutoff value (6). Thus, successful prevention and 
management of increasing metabolic abnormalities and related cardiovascular and 
type 2 diabetes illnesses require accurate identification of high-risk individuals (1). 
There has been a growing research interest in practical, sensitive, screening cut-off 
values that are appropriate for different population groups worldwide. The overall 
objective of these research interests is to detect obesity and relative me abolic 
syndrome risk criteria.   
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The existing cut-off values for WC were adopted by International Diabetes 
Federation (IDF), and National Cholesterol Education Program - Adult Treatment 
Panel (NCEP-ATP III). They were based on studies of Europeans with limited sample 
size that related WC to BMI (2, 7, 8) in men and women. The NCEP-ATPIII waist
circumference ≥ 102 cm in men and ≥ 88 cm in women were predicted from the BMI 
of 30 kg/m², and the IDF WC ≥94 cm in men and ≥ 80 cm in women were predicted 
from the BMI of 25kg/m². Furthermore, the data did not take into consideration other 
metabolic syndrome components including high blood pressure, elevated fasting 
blood glucose, high levels of triglycerides, and low high density lipoprotein 
cholesterol (HDL-C). In addition, the age, gender and ethnic dependent relationship 
of waist circumference to abdominal adiposity were not addressed in the initial 
NCEP-ATP III guidelines. For instance in other studies, cutoff values developed by 
NCEP-ATP III were later found to be inappropriate for certain groups, such as 
Asians, whose WC/BMI display higher morbidity at lower cutoff points than 
European Americans (6). This led researchers to question the use of universal WC cut 
off values. Consequently, other research suggested that an evaluation was needed to 
determine if the current IDF and NCEP cutoffs are sensitive indicators of risk fo  
other ethnic groups.  
Given that waist circumference cutoffs have been found to be more predictive of 
body fatness, fat distribution (3, 9-11) and metabolic risk factors (12) in some 
population groups and inappropriate for others. IDF has recognized this and proposed 
to lower the waist circumference cut-offs for some ethnic groups. These new IDF 
ethnic cut-off values were not always validated against clinical outcomes and im ging 
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data of visceral fat (4). Also, previous studies on WC cut off points in African 
Americans were limited and not inclusive of the clustering of MetS abnormalities 
(13-17) and depended on BMI, indicating inadequate attention to high risk central 
obesity. 
Studies show that there are health disparities between African Americans and 
other USA minorities indicating that they are at higher risk for morbidity and 
mortality from non-communicable chronic illnesses associated with metabolic 
syndrome. However, studies using the NCEP-ATPIII criteria report lower rat s of 
metabolic syndrome  in African Americans (AA)  (12),  and this is in contrast with 
observed disproportionately high prevalence of obesity, insulin resistance, type 2 
diabetes, hypertension and heart disease (18,19). These lower rates of metabolic 
syndrome were  attributed to lower levels of certain major components of metabolic 
syndrome, specifically serum high-density lipoprotein cholesterol (HDL), 
triglycerides (TG) (20, 21) and lower waist circumference (WC) particularly in men 
(7,16,17). The latter has been confirmed in a study which reported WC cutoffs 5-6 cm 
greater for European Americans (EA) than for AA men at every BMI levelfrom 25 to 
40 kg/m², while  no differences in WC for women was reported (16).  
The use of WHO BMI to characterize CVD risk factors in determining WC was 
also a problem because the BMI cut off values of overweight (25 kg/m²) and obesity 
(30 kg/m²) had several limitations (10, 22). BMI does not separate fat mass from fat 
free mass (muscle, skeletal masses) (3). Also, studies have demonstrated that 
individuals with identical BMI values may have considerably different percentag  fat 
levels, particularly if they vary in age, gender and ethnicity. African Americans in 
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particular, have been reported to have higher total bone density and muscle mass 
content compared to European Americans (10, 23). Other studies have observed 
higher values of skeletal muscle mass among African American males and females 
across their lifespan compared to other ethnic groups as illustrated in Figure 1 (24).  
Recently, Flegal et al., 2009 investigated the relationship between BMI, WC, and 
waist-stature ratio (WSR) as proxies for adiposity with percentage body fat (% BF) in 
12,901 individuals > 18 years of age from the 1999-2004 NHANES national sample. 
They confirmed differences in percentage body fat at the same BMI percentiles 
among different ages, sex, and ethnicity as stated previously.  At a given BMI, the 
percentage of body fat, estimated using dual energy X-ray absorptiometry (DEXA) 
method, was lower in African Americans than in the European Americans, and 
further research was recommended to determine BMI, WC, and WSR that best 
classify individuals according to percentage fat (25). 
Fig1: SKELETAL MUSCLE FOR ETHNIC GROUPS BY AGE & GENDER  
(Source: Analiza M. Silva et al., 2009 - American Journal of Human Biology 1-7) 
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It is recognized that differences in body composition in ethnic/racial groups affect 
the cut off values for measurements of abdominal and overall obesity (6,26,27). 
Given the increased skeletal muscle mass and lower % BF, the relationship between 
% fat and BMI probably is different among African Americans. The change in this 
relationship suggests that African Americans, men in particular, may be at decreased 
metabolic risk compared with Europeans at a similar WC and BMI (12). Since these 
population groups may differ in the level of risk associated with a particular 
BMI/WC,  research is needed to determine appropriate African American WC and 
BMI cut points to account for differences in (i) susceptibility to obesity-related 
metabolic risk factors, (ii) the relation of BMI to body fatness and fat free mass, and 
(iii) fat distribution.  
This study focused on appropriateness of WC and BMI cut offs in African 
American males and females and determined optimum waist circumference and BMI 
based on their specific MetS risk factors. The results will contribute to the 
understanding of ethnic differences in metabolic syndrome profile and its implication 
in chronic disease disparities. To our knowledge, this will be the first study to assess 
the WC and BMI considering the unique characteristics of this group in terms of 
existent metabolic syndrome risk factors among African Americans, their higher 
muscle mass, bone density and lower body fat at a given BMI. It is anticipated th  
this study will initiate further interest to research the underlying metabolic syndrome 
differences and clarify the contribution of each MetS parameter to the higher 






1. To determine gender specific waist circumference cutoff values and body 
mass index for detecting  the clustering of  metabolic risk factors among 
African Americans ≥ 20 years independent of WHO BMI cutoff values; 
2. To identify the cutoff values for waist circumference and BMI by ten-yar age 
groups (20-29; 30-39; 40-49; 50-59; 60-69; and 70+). 
3. To investigate whether there are differences in the likelihood of having 
metabolic syndrome based on the WC/ BMI cutoff values estimated by this 
study in comparison with the NCEP-ATP III, IDF and WHO cutoffs. 
 
Secondary 
4. To identify differential metabolic risk characteristics among African 
Americans men and women that characterizes individuals with and without 
metabolic syndrome. 
5. To determine the possible environmental and health determinants (dietary, 
nutritional biochemistries, hepatic fat accumulation markers, inflammation 
and thrombotic markers, hyperuricaemia, microalbuminuria, thyroid 
abnormalities, socioeconomic and lifestyle factors) that may contribute to 
MetS among African Americans adults ≥ 20 years when comparing those with 






3.1. What are the threshold values for waist circumference and BMI in adult African 
Americans that would predict the presence of individual and ≥ 2 metabolic syndrome 
risk factors (low HDL cholesterol level, high triglyceride level, high glucose level, 
and high blood pressure) by gender?  
3.2. Which WC cutoff values are appropriate among those suggested by current 
study, NCEP-ATP III, and IDF, for the criteria of WC as a component of the MetS 
syndrome among African Americans? 
3.3. Is there a statistically significant difference in age-adjusted prvalence of MetS 
among adult African Americans using a modified NCEP-ATPIII based on WC from 
question 3.1 compared with NCEP- ATPIII and the IDF definitions?  
3.4. What are the threshold values for waist circumference in adult African 
Americans that would predict the presence of ≥ 2 (3) metabolic syndrome risk factors 
by ten-year age groups and gender?  
3.5. How do the gender-specific cutoff values of WC/BMI for detecting ≥ 2 metabolic 
syndrome risk factors compare among cases with raised blood pressure (SBP ≥ 130 
mmHg and/or ≥ 85 mmHg) and those without raised blood pressure using ROC 
analysis? 
3.6. Is there a statistically significant difference in MetS components and age-
adjusted prevalence of  ≥ 2 and 3  metabolic syndrome risk factors based on BMI 
from question 3.5 compared with WHO cutoff values (25kg/m² and 30 kg/m²)?  
3.7. What are the predictors of MetS among African Americans men and women, and 
is there a statistically significant difference in concentration for TG and HDL among 
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African Americans diagnosed with ≥ 2 metabolic syndrome risk factors and those 
without MetS?  
 
Supplemental Research Questions 
1. Is there a statistically significant difference in the dietary variables ( total Kcal, 
fat, carbohydrate, protein, fiber, vitamin C, Carotene, vitamin E, selenium, 
(antioxidants), Iron between individuals diagnosed with ≥ 2 metabolic syndrome 
risk factors and those without MetS? 
2. Is there a statistically significant difference in serum vitamin C, Carotene, vitamin 
E, selenium, (antioxidants), Iron between individuals diagnosed with ≥ 2 
metabolic syndrome risk factors and those without MetS? 
3. Is there a statistically significant difference in relevant hepatic blood test  - ALT 
alanine Aminotransferase,  ALP alkaline phosphatase, GGT gamma glutamyl 
transferase between individuals diagnosed with ≥ 2 metabolic syndrome risk 
factors and those without MetS? 
4. Is there a statistically significant difference in the inflammation and thrombotic 
markers, hyperuricaemia and microalbuminuria between individuals diagnosed 
with ≥ 2 metabolic syndrome risk factors and those without MetS? 
5.  Is there a statistically significant difference in socioeconomic variables (poverty 
income ratio, education, or marital status) and lifestyle factors (physical activity, 
alcohol, cigarette intake) between individuals diagnosed with ≥ 2 metabolic 
syndrome risk factors and those without MetS? 
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CHAPTER 2: BACKGROUND AND LITERATURE 
REVIEW 
 
2.1. Metabolic Syndrome 
The term metabolic syndrome (MetS) has been developed with the purpose to 
assist in identification of individuals at high risk of type 2 diabetes and cardiovascular 
disease (CVD) in order to put in place preventative measures that can decrease their 
risks (28-30). Although no accepted central underlying mechanism has been agreed 
upon (31) for the pathogenesis of the Metabolic Syndrome, two features: the visceral 
obesity (32,33) and impaired insulin in particular (34-36) stand out as potential 
etiologies underlying the associated abnormalities of MetS.  Additional indepe nt 
mechanisms that have been considered as important contributors to the MetS include: 
prenatal and early-life influences (37); chronic stress; chronic activation of the 
immune system; the contributions of cytokines, hormones and other molecules 
produced by adipocytes;  disorders of the hypothalamic–pituitary–adrenal axis; and 
altered glucocorticoid hormone action (31,38). Aging and hormonal changes (34) as 
well as potential multiple gene combinations (39) have also been implicated in the 
development of MetS. 
Impaired insulin action in the liver, muscle and adipose tissues have been 
considered as the core disorders  in the MetS  and at the origin of risk factors  that 
tend to cluster together as well as to occur commonly in insulin resistant individuals 
(36,40). The risk factors include hypertriglyceridemia, low high-density lipoprotein 
cholesterol (HDL-C), hyperinsulinemia, and high blood pressure (36).  The 
simultaneous occurrence of these metabolic abnormalities has been shown to confer 
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higher cardiovascular disease (CVD) risk than each abnormality taken individually 
(41) or the sum of the abnormalities (42,43), even in the absence of hyperglycemia or 
diabetes (35). Patients with MetS have risk of developing CVD over the next 5 to 10 
years is twice that of individuals without the syndrome.  In addition, individuals with 
MetS have a 5 fold increase in risk for type 2 diabetes (29).  A meta-analysis of 
longitudinal studies confirmed a 2 fold CVD risk for MetS which remained 
significant after controlling for classical CVD risk factors (44). Data from the 
NHANES III was used to quantify the increased prevalence of CHD among adults (> 
50 years of age) by presence of MetS with or without diabetes. The results showed 
the lowest coronary heart disease (CHD) prevalence among individuals without 
metabolic syndrome regardless of diabetes status. A marked increase in prevalenc  of 
CHD was observed with the presence of metabolic syndrome, and the prevalence was 
highest when the diabetes and MetS co-exist (35). The risk of myocardial infarction, 
stroke, and coronary heart disease has been found to be much higher in individuals 
presenting with MetS than in those without the syndrome (45). Some studies, 
however, state that the MetS is not more useful than its collective component parts 
(46,47), while others argue that MetS has a longer-term prognostic value for CVD 
than that achieved by short-term global risk calculators (48).  
  The introduction of this complex of interrelated risk factors was originally 
called syndrome X or insulin resistant syndrome, and now it is referred to as 
metabolic syndrome. MetS is considered useful as a professional and public 
educational concept (53). Also, it represents an advance in health awareness nd 
preventative medicine and goes beyond the classical risk factors, such as elevated 
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cholesterol, smoking, hypertension, and diabetes, in identifying high risk individuals 
(23). Although progress has been made in the management of the conventional risk 
factors, obesity and the metabolic syndrome have dramatically increased in th  USA 
and other developed countries (4,49)  and  MetS is related to the increase in morbidity 
and mortality of cardiovascular diseases (32). Recent studies have shown an 
association between MetS and other clinical conditions including liver disease (50), 
cancer (51) and sleep apnea (52).  
2.1.1   Clinical Criteria for Metabolic Syndrome 
 
One of the objectives of the World Health Organization (WHO) Action Plan for 
the Global Strategy for the Prevention and Control of Non-Communicable Disease i 
to develop simple strategies to identify high risk individuals, and suitable and cost 
effective interventions (53).  The metabolic syndrome has been advocated as a 
simplified screening tool and as a framework for the exploration and understanding 
the pathophysiological association between metabolic abnormalities. The MetS 
allows us to quantify the comparison between different risk levels (relative risk) and 
to predict chronic disease risk factors within populations. Also, this screening tool 
facilitates comparisons between countries, guides clinical management decisions, and 
provides a public health message for the need to assess related risk factors (54).  A 
recent “Debate” report of a WHO Expert Consultation has recommended that the 
metabolic syndrome be considered as a pre-morbid condition (54) rather than a 
clinical diagnosis, and should thus exclude individuals with established diabetes or 
known cardiovascular disease (CVD).  
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 In the same line of preventative measures for CVD in particular and clinical 
management of high blood cholesterol and intensive treatment of patients with CHD, 
the NCEP –ATP III updated existing recommendations  and added a new major 
feature which focuses on the primary prevention in individuals with metabolic 
syndrome. The preventive approach is to primary use intensified therapeutic lifs yle 
changes (1, 2), then drug treatment on the individual components if the latter fails (1). 
Moreover, NCEP-ATPIII recommended a complete lipoprotein profile (HDL 
cholesterol, triglycerides, total, and LDL) screening once every 5 years for 
individuals 20 years or older, as opposed to the initial test for HDL and total 
cholesterol alone.  
 Currently, there is no universally accepted definition of metabolic syndrome. 
A number of independent organizations WHO (55), NCEP-III (32), the European 
Group for the Study of Insulin Resistance (56) and the IDF (1) have proposed clinical
criteria for clinicians for identification of high-risk individuals and for research (30). 
All groups agree on the core criteria of the MetS including dyslipidemia, obesity, 
insulin resistance, and hypertension (57). The most widely used clinical criteria for 
diagnosing the MetS are those proposed by IDF, and the NCEP -ATPIII.  Their 
definitions include the risk factors listed in table I, and there is use of different cut-off 








Table I Clinical diagnosis of the metabolic syndrome based on criteria from the NCEP ATP 
III, WHO, and consensus criteria for NCEP-ATPIII and IDF 
NCEP ATP 
III a WHOb 
 





≥100 mg/dL IFG/IGT/T2DM ≥100 mg/Dl (5.6 mmol/L) 
Or treatment of elevated glucose 
If above 100 mg/dL (5.6 mmol/L), 
OGTT strongly recommended but not 
necessary 
 
Abdominal obesity    
  en ≥102 cm 
WC 
>0.90 WHR (or BMI ≥30 kg/m2) * Ethnicity specific 
Europids ≥ 94 cm 
South Asians/Chinese ≥ 90 cm 
Japanese ≥ 85 cm 
 
  Women ≥88 cm WC >0.85 WHR (or BMI ≥30 kg/m2) Europids ,South Asians/Chinese ≥ 80 
cm 
Japanese ≥  90cm 
 
Triglycerides ≥150 mg/dL ≥1.7 mmol/L ≥150 mg/dL (1.7 mmol/L) 
treatment for this lipid abnormality as 
alternative indicator 
 
HDL Cholesterol   
  Men <40 mg/dL <0.9 mmol/L <40 mg/dL (1.03 mmol/L) or drug 
treatment for reduced HDL-C 
 
  Women <50 mg/dL <1.0 mmol/L <50 mg/dL (1.29 mmol/L) 
 
 
Blood pressure ≥130/85 mm 
Hg 
≥140/90 mm Hg ≥130/85 mm Hg 
Treatment of previously diagnosed 
hypertension 
 
Microalbuminuria – Yes -  
 
 
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; 
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, 
type 2 diabetes mellitus; NCEP ATP III, National Cholesterol Education 
Program Adults Adult Treatment Panel III; WC, waist circumference; 
WHO, World Health Organization.  
WHR, waist-to-hip circumference 
ratio 
aThree or more criteria. 




According to the WHO definition of MetS proposed in 1998, MetS is 
diagnosed on the basis of insulin resistance as defined by impaired fasting glucose, 
type 2 diabetes, or glucose intolerance plus two additional risk factors. The other risks 
include high body mass index or waist-to-hip circumference ratio; elevated plasma 
triglyceride; decreased plasma high density lipoprotein cholesterol; hypertension; or 
elevated urinary albumin (58). 
 The International Diabetes Federation (IDF), and the NCEP ATP III 
definition both consider that a person with MetS has at least 3 of the 5 metabolic 
abnormalities: elevated triglycerides, low HDL cholesterol, hypertension, elevated 
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fasting blood glucose or impaired fasting glucose or type 2 diabetes mellitus, and 
ethnic specific abdominal obesity (2,29,57).  Individuals on medication for high blood 
pressure, type 2 diabetes, and dyslipidemia are included in the diagnosis of MetS (1). 
The most recent (2003) fasting blood glucose of 5.6 mmol/L or 100 mg/dL was 
adopted by both IDF and NCEP –ATPIII. However, the shortcoming of this new 
definition of impaired fasting glucose is that it would not capture a substantial 
number of individuals with impaired glucose tolerance as the oral glucose tolerance 
test (OGTT) is not required (59). Other components commonly observed among 
individuals with MetS such as inflammatory and thrombotic markers, hyperuricemia 
and microalbuminuria have been suggested to be included in further studies as criteria 
of the MetS (60). 
Concerning the WC, IDF recommends a threshold for WC ≥ 94 cm for men 
and ≥ 80 cm equivalent to a BMI of 25 kg/m² for women of European origin. Ethnic 
specific WC thresholds included in the IDF definition were based on data linking WC 
to diabetes status for Asian Indians, and WC to obesity related multiple risk factors 
for other Asian populations (61-63). In contrast, the AHA/NHLBI recommends the 
WC ≥ 102 cm and ≥ 88 cm values for men and women, respectively, to define 
abdominal obesity. The latter values are consistent with the definition of abdominal 
obesity found in National Institutes of Health obesity guidelines (64), and are 
equivalent to a BMI of approximately 30 kg/m².  The NCEP-ATPIII recognizes that 
some male patients may be genetically predisposed to insulin resistance and can be 
diagnosed with multiple metabolic abnormalities when their waist circumferenc  is 
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only marginally increased (94 -102cm). As a result, they should be targeted to change 
life habits (2). 
 In an attempt to unify the criteria, a 2009 meeting of the IDF, NHLBI, 
American Heart Association, World Heart Federation, International Atheroscl r sis 
Society, and the International Association for the Study of Obesity reached an 
agreement that both the IDF and NCEP-ATPIII consider as alternative MetS 
indicators drug treatment for elevated fasting glucose, triglycerides, blood pressure 
and for reduced high density lipoprotein cholesterol (HDL-C) in their definitions (29).
They also approved that there should not be an obligatory component and waist 
circumference should continue to be a useful preliminary screening tool (29). 
Additionally, recommendations were made that a single set of cutoff values would be 
implemented for the components of MetS except WC for which further research is 
required. For the WC, it was recommended that the IDF WC cut off values be used 
for non-Europeans until more data is available. For people of European origin either 
the AHA/NHLBI or IDF should be used. Further cross-sectional and longitudinal 
studies were recommended to explore the relation of WC thresholds to metabolic risk 
factors for both CVD and type 2 diabetes, and to reach more reliable WC cut off 
values for different ethnic groups, especially for women.  Meanwhile, national and 
regional cut off values for WC would continue to be in use and three out of the 5 
MetS criteria would qualify an individual as having metabolic syndrome (29).  
Despite the many advantages of the MetS to identify people in both the 
community and clinical settings at increased risk of CVD and diabetes (1); in 
predicting CVD morbidity, CVD mortality, type 2 diabetes and all-cause of mortality 
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(38); and in guiding relative risk prediction and management decisions, the concept 
has been subjected to criticism for the lack of agreement upon a single unifying 
pathophysiological mechanism.  Other denunciations include the omission of some 
risk factors for predicting diabetes and CVD (e.g., direct measure of insulin 
resistance, family history, C - reactive protein), and lack of established risk factor 
cutoffs across different populations (65). The concept has not been widely adopted in 
formal diagnosis and national guidelines for the prediction of DM and CVD. In 2008, 
however, the Japanese Government initiated a national screening program using the 
MetS as the point of entry in identifying people at high risk, who can benefit from 
intervention to reduce CVD risk (66). The recent publication of a consensus statement 
on the definition of the MetS, representing the views of six major organizations and 
societies, may prove to be a pivotal point in the development of the MetS as a tool for 
clinical and public health use (67). 
 
2.1.2 The Prevalence of Metabolic Syndrome 
Studies have shown that the prevalence of MetS differs between genders, and 
among ethnic groups and countries. The condition is becoming increasingly common 
in many populations in developing world, and among younger age groups including 
overweight/obese adolescents (68,69). Differences in genetic background, diet, levels 
of physical activity, population age and sex all influence the prevalence of the MeS 
and its components (57). The MetS prevalence estimates, using different definitions, 
have been often found to be similar in some populations; however, in others, rates 
vary from one ethnic group to another (70,71).   
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The NHANES 1988-1994 data shows that the age-adjusted prevalence of 
MetS, based on ATPIII criteria, was 24% in the adult US Population (2). Based on 
NHANES III and NCEP-ATP III criteria, the MetS affects 47 million peo le in the 
United States, with the highest rates observed in Mexican American women and the 
lowest rates observed in African American men. The age-adjusted prevalence of 
MetS was 21.6% among African Americans and similar to that of the overall US 
population (23.7%). However, African American women presented with higher MetS 
occurrence of 25.7% than their male counterparts of 16.4% (Figure 2) (72). It has 
been observed that the higher prevalence of MetS, among African American women, 
is mainly related to the disproportionate rates of high blood pressure, overall obesity, 
and type 2 diabetes. The data based on NHANES 1999-2000 has shown a statistically 
significant increase in age-adjusted national prevalence of MetS from 24% to 27.0%, 
with higher increase particularly observed among women. Increases in high blood 
pressure, waist circumference, and hypertriglyceridemia accounted for much of the 
raise in MetS (87). 
FIG.2. Age-adjusted prevalence of three or more risk factors for the metabolic 
syndrome among US adults.  
 
 
Source: J Am Med Assoc 2002; 287:356-359. 
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In a succeeding study that used the NCEP  and the revised IDF 2005 definitions 
with elimination of  WC as a requirement for the diagnosis of MetS, the prevalence of 
any 3 of 5 risk factors were estimated among US adults ≥ 20 years of age from 
NHANES 1999-2004 data (12). For the NCEP definition, the unadjusted prevalence 
of MetS was 35.5% for women and 34.8% for men. For the revised IDF definition, 
the prevalence was 38.3% and 41.9% respectively in women and men. With the use 
of NCEP ATPIII higher WC cut points (102cm), a lower proportion of individuals 
were diagnosed as having MetS compared to the revised IDF 2005 lower WC 
threshold. African Americans had the lowest age-adjusted prevalence of MetS 
(24.5%) compared to African American women and other ethnic groups (>35%). 
Additional data shows that in the USA, the metabolic syndrome is very common, and 
an estimated 44% of the adult population over 50 years of age met the NCEP criteria 
(35).        
A recent study on racial differences in kidney function among 37,107 males with 
BMI ≥ 30 kg/m² and metabolic syndrome (73), found that European Americans were 
more likely to have MetS components. Hypertension was 87.1% vs. 84.8%, 
dyslipidemia was 81.6% vs. 66.7%, and diabetes was 42.7% vs. 34.9% in EA vs. AA 
respectively. However, African Americans men were more likely to have abnormal 
microalbuminuria levels (73).   
2.2 Insulin Resistance 
2.2.1. Insulin and Macronutrient Regulation  
Insulin is an important hormone and its binding to the receptor on the liver, 
adipose and skeletal muscle cells, initiates activation of the downstream signaling 
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molecules and pathways that mediates the effects of insulin on glucose, protein, lipid 
metabolism and cell division, differentiation and growth (74,75). Insulin regulates the 
whole body glucose homeostasis by promoting glucose uptake in the muscle, adipose 
tissue, and inhibiting glucose production through the process of glycogenolysis and 
gluconeogenesis in the liver. For the regulation of lipid metabolism, insulin increases 
esterification of free fatty acids and fatty acid synthesis. Insulin also reduces hormone 
sensitive lipoprotein lipase activity that result in decreased lipolysis and free fatty 
acid in the circulation, and inhibits the rate of Apoprotein B and very low density 
lipoprotein (VLDL) synthesis in the liver (76).  It is also evident that insulin increases 
protein synthesis and DNA replication by regulating the amino acid uptake and 
decreasing proteolysis (77).   
In insulin resistance, the normal production of insulin does not lead to normal 
insulin response. As a result pancreatic beta cell secretes more insulin to compensate 
for the hyperglycemic status commonly observed among individuals with MetS and 
type 2 diabetes. Animal and human studies have suggested that hepatic insulin 
resistance is the underlying cause of the MetS (78) and its related metabolic 
abnormalities, namely dyslipidemia, and increased inflammatory factors.  
2.2.2 Insulin Resistance, Central Obesity, and Metabolic Syndrome 
Series of metabolic studies have revealed that increased adipose tissue is 
associated with high levels of free fatty acids and insulin resistance (23,79). Although 
visceral fat depots account for a low percent of total body fat, for instance 15% in 
obese men (80), subjects with large visceral fat present the most severe metabolic risk 
profile and insulin resistance state (81,82). Studies have demonstrated that the 
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inflammation status associated with the increased secretion of adipokines from excess 
adipose tissue (49), and the alteration in free fatty acid metabolism are involved in 
insulin resistance pathogenesis by disrupting the insulin signaling cascade (83,84). 
This defect in post-receptor signaling has been indicated to be the primary cause of 
reduced insulin sensitivity of targeted tissues (85). Consequently, insulin resistance is 
then characterized by skeletal muscle and liver insulin resistance as well as the beta-
cell abnormalities (86), essential elements in the pathophysiology of type 2 diabetes. 
Additionally, insulin resistance is associated with an increase in adipose tissu
lipolytic rate, which plays an important role in pathogenesis of dyslipidemia 
associated with MetS (49) as discussed in the subsequent paragraph. Among obese 
individuals, the increased plasma insulin concentration lacks the ability to 
compensate for insulin resistance in adipose tissue, and these subjects present with 
high basal lipolytic rates and plasma NEFA concentrations (72). Insulin resistance 
can also cause vasoconstriction and renal sodium reabsorption, leading to high blood 
pressure (49).  
2.2.3 Insulin Resistance and Dyslipidemia   
The atherogenic dyslipidemia in patients with MetS consists of a reduced 
level of high density lipoprotein cholesterol and elevated serum triglycerides 
(2,72,88). Although not cited as criteria for the diagnosis of MetS, other lipoprotein 
abnormalities associated with insulin resistance and increased CVD risk include an 
increase in small low density lipoprotein particles, apolipoprotein B, small HDL 
particles and postprandial accumulation of triglycerides rich remnant proteins 
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(29,89,90). They have also been shown to be associated with increased CVD risk (91-
94).  
In a normal state, the hydrolysis of triglycerides to fatty acids and glycerol in 
fat cells is a process regulated by several hormones and parahormones which act on 
cyclic adenosine monophosphate (c-AMP) formation or breakdown. In turn the c-
AMP influences the activity of hormone sensitive lipase (HSL), which stimulates 
hydrolysis of triglycerides. The rate of lipolysis is highest in the visceral adipose 
tissue (VAT), intermediate in the subcutaneous abdominal fat, and low in the 
subcutaneous gluteal/femoral region (95).  
The alteration of free fatty acid metabolism condition is characterized by 
adipocyte resistance to the antilipolytic effect of insulin and the impairent of FFA 
esterification (96, 97). Thus, the excessive non-esterified free fatty acids (NEFAs) 
from the lipolysis of fat cells alter the ability of insulin to (i) stimulate muscle glucose 
uptake, (ii) inhibit hepatic glucose production - contributing to impaired glucose 
tolerance (98,99), and (iii) diminish the hepatic insulin clearance as discussed earli r.
Additionally, increased free fatty acid, mainly released from visceral adipocytes into 
the portal vein then to the liver, leads to an increase in hepatic secretion of 
triglycerides rich lipoproteins (VLDL) (23,100-101), in elevated plasma triglycerides 
concentration (102), in decreased hepatic degradation of apoprotein B and insulin - 
resulting in hyperapolipoprotein B and hyperinsulinemia. The lipid deposition and 





Figure 3: Altered Lipid Metabolism and Insulin Resistance 
Jean Pierre Despres, Annals of Medicine 2006; 38: 52-63. 
The high concentration of triglycerides rich lipoproteins, as seen in 
individuals with high visceral fat, enhances the transfer of triglycerides from VLDL 
to LDL and HDL, in exchange for cholesteryl esters. The effect of the increased 
cholesteryl ester transfer protein (CETP), in obesity, on the transfer of cholestery  
esters is presented in Figure (4).This process results in LDL and HDL particles high 
in TG, which are subject to lipolysis by the hepatic lipase enzyme. The increased 
activity of this enzyme, in viscerally obese patients (23), enhances the formati n of 
cholesteryl ester depleted small LDL and HDL particles.  This is largely esponsible 
for the observed higher clearance of HDL and its decrease in plasma found in MetS 
condition (103). The discussed pattern of dyslipidemia characterized by three lipid 
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abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol 
concentrations and the presence of small, dense LDL particles are also referred to as 
the “atherogenic lipid triad”. They are observed in individuals with MetS or type 2 
diabetes (104). It has been suggested that the clinical importance of the atherogenic 
lipoprotein phenotype probably exceeds that of LDL-cholesterol, due to many more 
patients with coronary artery disease that are found to have this trait than 
hypercholesterolemia (105). 
Figure 4: Mechanisms of cholesteryl ester transfer protein 
 
It has been suggested that the role of the insulin resistance and abnormal fat 
distribution may vary depending on ethnic group (57). Hyatt et al., 2009 study in 
A.Bakhai et al., 2008  QJ Med 2008; 101; 767-776 
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premenopausal, healthy and overweight women, showed that African Americans are 
more hyperinsulinemic than European Americans, independent of obesity, fat 
distribution, and inflammation (106). The insulin resistance in AA has been reported 
to be highly associated with subcutaneous adipose tissue, thus the overall body 
fatness could be the important mediator in disease process (82,107) among African 
Americans men and women.    
Although issues have been raised concerning the absolute cut points of plasma 
TG and HDL –C proposed by the NCEP-ATP III, there is ample data suggesting that 
these atherogenic dyslipidemia criteria are characteristic of insulin resistance and 
highly predictive of CVD risk, and their treatment lead to a decrease in incidence of 
CVD (108). In general, the distribution of triglycerides, HDL-C and TG/HDL-C ratio 
appear the same between adult US males and females. However, African Americans 
have lower levels of triglycerides and small LDL particles than EA (109), and AA 
men have higher levels of HDL-C than their EA counterparts (28). Among females, 
AAs seem to have similar or lower triglyceride concentrations and comparable HDL-
C concentrations to EA females (20,110). The coexistence of insulin resistance and 
lower levels of triglycerides in AA has been associated with the lack of the efect of 
insulin resistance to hinder the increased lipoprotein lipase activity to clear the TG 
(20).  
 Stein E. et al. 2007 reported that among a sample of African Americans, only 
10% of the sample (n=185 non diabetic AA 30-50 years of age) had TGs ≥ 150 
mg/dL. Individuals with TG levels of 110-149 mg/dL (>110mg/dL) presented insulin 
resistance equivalent to that of the high – TG ≥ 150 mg/dL group and concluded that 
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the TG levels below the current ATPIII MetS cut off value are associated with insulin 
resistance. The authors suggested that a TG value of ≥ 110 mg/dL increased the 
detection of the MetS at different levels of insulin resistance (21). 
2.2.4. Insulin Resistance, Adipokines and Atherosclerosis  
The adipose tissue stores and releases energy rich fatty acids, and it is now 
recognized as an important secretory organ of bioactive proteins, namely adipokines. 
Increased abdominal obesity with a predominance of visceral adipose tissue is 
associated with an increase rate of lipid metabolism and adipokines secretion than in 
subcutaneous fat. The cytokine molecules produced by the adipose tissue, although 
many of them are produced by other cells and tissues, include interleukin-6 (IL-6),
angiotensinogen, resistin, plasminogen activator inhibitor (PAI-1), and tumor necr sis 
factor- α (TNF-α). Leptin and adiponectin are exclusively produced by adipose tissue.  
In contrast to other adipokines, the levels of adiponectin, an anti-inflammatory and 
insulin sensitizer are decreased in obese individuals (112).  
The rise in plasma level of the proinflammatory cytokines secreted by adipose 
tissue (TNF- α, IL-6, and leptin, PAI-1, angiotensinogen, resistin) as well as acute-
phase proteins such as c-reactive protein (CRP) increases along with increas g 
adipose mass. It is more evident that this state of chronic inflammation may 
contribute to the chronic illnesses associated with obesity, namely atherosclerosi , 
dyslipidemia and insulin resistance (113).  Additionally, CRP is emerging as an
independent and strong predictor of cardiovascular diseases (114,115). 
 Adipokines play crucial roles in the development of atherosclerotic plaques 
and insulin resistance (Figure1). The adipokines raise the migration and attachment of 
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monocytes in the blood vessel wall and their conversion into macrophages. The 
macrophages phagocytose oxidized LDL resulting in formation of lipid laden foam 
cells.  As the foam cells accumulate in the vessel wall, they form fatty streaks which 
develop into atherosclerotic plaques (116). Adipokines have been show to contribute 
to the increase release of non-esterified free fatty acids (NEFAs), and high levels of 
adipokines and NEFAs from the excess adipose tissue lead to insulin resistance 
(117,118). The tumor necrosis factor α adipokine down regulates the insulin signaling 
cascade, including the expression and translocation to the cell membrane of the 
GLUT 4 glucose transporters. Thus, this results in impaired ability of insulin to 
stimulate glucose uptake by muscles and adipocytes, (117) and the ability of insulin 
to suppress hepatic glucose production is impaired (119).  
2.2.5. Insulin Resistance and Non-Alcohol Fatty Liver Disease 
Non-alcoholic fatty liver disease (NAFLD) refers to liver damage that ranges 
from simple fatty liver to steatohepatitis, characterized by advanced fibrosis and 
cirrhosis. NAFLD is defined by the accumulation of fat in the liver >5% per liver 
weight with a minimum < 10 g daily alcohol intake (120). Approximately 33.6% 
cases of NAFLD have been diagnosed in a population based on a cohort study in the 
USA (121). NAFLD is strongly related with insulin resistance and metabolic 
syndrome (122). Waist circumference, TG level and insulin resistance have been 
shown to be independently associated with NAFLD. The latter is the most frequent 
reason of elevated liver enzymes in the USA among individuals diagnosed with 2 
diabetes, obesity and hyperlipidemia (123). The excess fat deposition in the liver has 
been associated with increased free fatty acids delivery from adipose tissues, elevated 
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synthesis of fatty acid via the de novo pathway, high consumption of dietary fat, and 
reduced clearance of VLDL particles (120).  
Currently, the liver biopsy is the “gold standard” procedure to diagnose 
NAFLD. Due to its invasive nature, the magnetic resonance spectroscopy/imaging 
and the computer tomography are used instead. There are no specific biochemical 
markers for NAFLD, however, an increase of alanine aminotransferase (ALT) is 
often used. Prospective studies have indicated an increase in gamma 
glutamyltransferase (GGT) with NALFD and could be considered as a surrogate 
marker of NAFLD (124,125).  
2.2.6. Hypertension and Metabolic Syndrome  
Approximately one in four persons in the United States presents with 
hypertension, which is twice more common in adults with diabetes than others. 
Obesity is possibly the common link between the two conditions; however, other 
factors namely autonomic dysfunction and insulin resistance may also be involved 
(127-129).  Insulin resistance has been proposed as a strong predictor for the 
development of hypertension (130). It has also been documented that patients with 
hypertension vs. those without it, have higher proportional frequency of some 
established cardiovascular risk factors, namely obesity, BMI, and family history of 
coronary artery disease. There is emerging evidence regarding a relationship between 
C-reactive protein (CRP) and hypertension (131).  
Elevated blood pressure contributes to microvascular and macrovascular 
complications, and to prevent those risks, reduction in blood pressure has been 
suggested. Guidelines from the American Diabetes Association and National Kid ey 
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Foundation recommend that blood pressure be reduced to less than 130/80 mm Hg, 
with an optimal target of below 120/80 mm Hg in individuals with renal insufficiency 
and proteinuria (132,133). A new category of hypertension classification has been 
introduced by the 7th report of the Joint National Commission (JNC-7) on High blood 
pressure. systolic blood pressure between 120-139 mmHg or diastolic blood pressure 
that ranges between 80-89 mmHg are indicative of  prehypertension, which is a 
strong predictor for the development of hypertension (134). Subjects with 
prehypertension have clinical characteristics of insulin resistance syndrome and tend 
to be more obese, have higher levels of fasting triglycerides and fasting insulin leve  
> 12.2 µU/mL, an established marker for IR (130). 
Studies demonstrate that there are striking hypertension disparities among 
ethnic groups. High blood pressure is more common in racial/ethnic minority groups 
than in European Americans and the consequences of hypertension-related illnesses 
are greater in these groups, particularly in African Americans. African Americans 
develop hypertension at an earlier age and the overall mortality owed to high blood 
pressure and its consequences is 4 to 5 times more likely in AA than in EA (135). 
This is due to a combination of genetic and mainly environmental factors.  
 
2.3 Abdominal Obesity 
2.3.1. Waist Circumference and Metabolic Syndrome   
In epidemiologic studies, WC is used as a simple measure of total abdominal 
size, and is considered as a valid marker of visceral fat (13), with thresholds that are 
gender and ethnic-group specific whenever available (29). Waist circumference is 
useful beyond the information provided by the BMI, and helps to identify the 
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subgroup of overweight/obese likely characterized by a greater accumulation of 
abdominal fat – the high-risk obesity phenotype (136). The WC is influenced by body 
composition, adipose tissue distribution, and body weight (3).  Relationships between 
gender, sex hormones, parity, menopause, and age with WC have also been noted 
(137,138). Based on NHANES data, the WC is larger in adult males than females 
except among AA (139), and  larger in older adults (60-69 years) compared to 
younger adults (20-29 years)  up to the age of 70 ( 140). Accumulation and 
redistribution of fat from subcutaneous to visceral fat have been observed from late 
middle age (141) and there seems to be a preferential accumulation of visceral fat 
post- pregnancy (142).  Other factors such as smoking and alcohol consumption have 
been found to be independently associated with increased WC in a longitudinal study 
(143). 
  Waist circumference has been determined to be better correlated with the 
abdominal visceral fat, estimated by computer tomography (5) than either BMI or 
WHR (8,139,144), and visceral fat has been shown to be more metabolically active 
than other fat stores. Visceral fat is highly associated with metabolic anormalities 
including glucose intolerance, hyperinsulinemia, hypertension, high LDL, high 
triglycerides, and high total cholesterol. Recently, Non-Alcohol Fatty Liver (NAFL) 
has been identified with respect to elevated metabolic risk (145). Consequently, large 
WC likely reveals increased NAFL and visceral adipose tissue (VAT). The WC 
ability to provide a crude but effective measure of intra-abdominal fat has not been 
observed in all subjects. However, in the presence of an increased waist 
measurement, high levels of fasting triglycerides may constitute a simple but useful 
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marker of the inability to store the extra energy in subcutaneous adipose tissues (145). 
There is now evidence that the simultaneous presence of a high WC and fasting 
triglyceride levels, described as hypertriglyceridemic waist, maybe a first step 
approach to identify a subgroup of individuals at higher risk of having features of the 
MetS such as atherogenic metabolic triad (high apolipoprotein B, small LDL, and 
hyperinsulinemia) (146).  
 Increasingly, studies have reported that central obesity is a more powerful 
predictor of chronic diseases, mainly hypertension, type 2 diabetes, and dyslipidemia, 
than overall obesity estimated with BMI (8,147-148). The abdominal obesity is 
highly correlated with insulin resistance and strongly correlated with the other MetS 
components than any other metabolic risk factor (33, 149). Among equally 
overweight or obese individuals, those characterized by an increase waist 
circumference are at increased risk of Type 2 diabetes and CVD (151), independent 
of the risk predicted by increased BMI. Furthermore, it has now been documented in 
prospective and case-control studies that individuals with a normal BMI, 
nevertheless, characterized by an excess visceral adipose tissue show the features of 
the MetS and have a two to three fold increase in CVD (152,153). Various studies 
have also shown that the association between WHR or waist to height ratio (WTR) 
and impaired glucose metabolism of type 2 diabetes was associated with larger w ist 
circumference and smaller hip or thigh circumferences (154,155).   
With the development of imaging techniques to accurately estimate abdominal 
adiposity and to discriminate subcutaneous fat from visceral, several studies have 
shown that central fat accumulation accompanied by an excess of intra-abdominal 
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adipose tissue is predictive of the features of the MetS (33,156), and the studies 
confirmed that individuals with an excess of visceral adipose tissue are characterized 
by the most severe metabolic abnormalities (5). Conversely, other studies found that 
subcutaneous abdominal fat is more closely related to insulin resistance than visceral 
fat (80,107). 
The hypotheses relating abdominal fat stores to the MetS focus on the 
established and emerging understanding that visceral adipose tissue in particular is a 
source of tumor necrosis factor-alpha (TNF-α) and of  FFA directly released into the 
portal vein, that impair insulin action in skeletal muscle (157). In addition, excessive 
adipose tissue is associated with a decreased production of adiponectin which may 
impair insulin sensitivity (158). The adiponectin is an adipose specific collagen-like 
molecule, which has been found to have anti-atherosclerotic, antidiabetic, and anti-
inflammatory functions. However, much work remains to be done to elucidate the 
complex interactions between central obesity and other MetS risk factors (159).  
 
2.3.2. NCEP-ATPIII and IDF Adopted WC Cutoffs 
 
Waist circumference cutoffs are unrelated to height and age, and closely 
related with total body fat and BMI (3,281,147,160). The waist circumference values 
were originally determined based on a study of Europeans relating WC to BMI to 
identify subjects that would benefit from weight management. A random sample of 
men and women were recruited from the general population of North Glasgow and 
their WC was measured mid-way between the iliac crests and the lowestrib. The 
cross tabulation between WC and BMI at ≥ 25 kg/m² and ≥ 30 kg/m²was assessed. 
The sensitivity and specificity for WC cutoff values were subsequently estimated.  
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For the BMI ≥ 25 kg/m², the WC were 94 cm and 80 cm, respectively, for men and 
women. Corresponding WC for the BMI ≥ 30 kg/m² were 102 cm and 88 cm. Both 
action levels of WC showed high sensitivity (>94%) and specificity (97%) for 
identifying individuals who required weight management.  The lower WC thresholds 
of 94 cm and 80 cm represent the cut points at which health risk were increased 
especially for young men. The upper WC cut off values of 102 cm and 88 cm 
coincide with the points at which the overweight related arthritis symptoms and signs 
of breathlessness started to develop (144). 
The cut-points for central obesity adopted in the USA by the National 
Institutes of Health clinical guidelines for obesity are 102 cm for men and 88 cm for 
women. These cut points are employed by NCEP - ATP III to define central obesity 
(2). In Europe, the WC of 94 cm in men and 80 cm in women are being used (57). 
The issue of whether these cutoff points might not be appropriate for different ethnic 
groups has not been settled, and the relationship between WC and BMI in Europeans 
may not apply to other ethnic groups (7,13,108,161). In recent years, some countries 
and organizations have estimated ethnic specific WC guidelines for instance for 
Asians and central and south Americans (7). 
 
2.3.3. Prevalence of Abdominal Obesity and Average WC in the USA 
An earlier study (Osokun et al, 2000) using NHANES III data shows ethnic 
differences in the prevalence of central obesity (102cm) across age groups (17-39; 40-
59, and 60-90). European Americans (EA) men had significantly higher prevalence of 
central obesity (14.1%, 30.5% and 50.6%) compared to African Americans (AA) 
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(5.5%; 11.7%, 37.6%). Among women, the prevalence of central obesity (88cm) was 
50%, 57.8%, and 57.4%, respectively, in EA, AA, and Hispanic Americans (HA) 
(17). 
A recent study, comparing ten year trends in WC and BMI in the USA, shows 
that for both NHANES III (1988-1994)  and NHANES 1999-2004,  AA men have a 
lower mean WC than EA (91.9  and  95.7 cm in AA vs. 96.3 and 100.9 in EA).  Over 
time, the difference in mean WC seems to have widened when comparing European 
Americans to African Americans (e.g., 4.4 cm vs 5.2 cm in men). Conversely, among 
females, the highest increase in mean WC was observed among AA (92.6 -98.4cm) 
vs. the EA (88 -92.7 cm) and the disparity in mean WC increased from 4.6 to 5.7 cm. 
Moreover, the ten year trends assessment in WC and BMI showed that the largest 
absolute increase in mean of WC and BMI in the USA population was constantly 
observed among the youngest adult (20-29 years), those aged 60-69, and AA females 
( 162). 
2.3.4. Racial Differences in Visceral and Subcutaneous Adipose Tissue 
Ethnic differences in the relationship of body fat and visceral adipose tissue 
have been reported.  At any level of total body fat, European Americans are more 
prone to elevated visceral fat deposition than African Americans (163). In the Health, 
Risk Factors, Exercise Training, and Genetics (HERITAGE) study of 723 healthy and 
sedentary AA and EA adults, Despres et al., 2000 observed an average VAT of 109 
and 74 cm² among EA men and women respectively, while the corresponding 
numbers were 74 and 67 cm² for AA. Within the African American group, despite 
higher total body fat among African American women than men, there was no gender 
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difference in absolute amount of visceral fat, and women were less prone to visceral 
fat accumulation than were men. Although both AA and EA men had similar body fat 
mass and BMI, EA showed significantly higher VAT than AA men. Among women, 
both EA and AA groups had similar levels of VAT. However, AA women had higher 
BMI, body fat, subcutaneous fat, body weight, WC, and %BF than their EA 
counterparts. Other studies have also reported that AA women had lower amounts of 
VAT for a given waist circumference, BMI, or waist to hip ratio (WHR) than EA 
women (164,165).   
 The findings comparing AA and EA were confirmed in a recent small sample 
study among both men and women from AA and EA. Although age, BMI, WC, 
WHR, and sagittal diameter did not differ among groups in either men or women, 
VAT was significantly lower in AA men and women (174). In addition, similar or 
greater concentrations of selected inflammatory biomarkers (fibrinogen, CRP, IL -6) 
were observed among AA. The researchers also found that SAT was more 
consistently associated with inflammatory markers after controlling for age, and 
VAT; suggesting a relationship between increased rates of inflammation and relted 
diseases, including insulin resistance and type 2 diabetes. Further research was 
recommended to assess the generalizability of their findings in a larger sample of 
different age, health status and locations.  
2.3.5. Estimated WC among African Americans 
In the Sumner et al., 2008 study, the authors determined the WC in African 
Americans which would best predict the insulin resistance (IR) based on a relatively 
small, convenient sample of healthy individuals 20-50 years old.  Their focus was on 
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the relationship of WC to insulin resistance (IR) and not MetS markers. Their 
rationale was that due to close association of visceral fat with both IR and WC, they 
could speculate that WC could be a marker of IR. Sixty eight men and 63 women 
participated in the study and their WC was measured and a mean of three 
measurements was recorded. WC and BMI cut-points that identified IR, as well as the 
WC prediction of BMI were investigated. WC was examined at 2 cm increment from 
≥ 80 to ≥ 108 cm.  The WC thresholds that optimally predicted the IR were 102 cm in 
men and 98 cm in women. This study did not consider all the MetS risk factors, and 
suggest a different WC for women. This study could not show that those individuals 
with WC consistent with IR were at highest risk of MetS (13).   
 
 Other studies have also suggested different WC cutoff values. Diaz et al., 
2007 examined the differences in the prevalence of diabetes and its association with 
WC, WHR, and BMI in different ethnic groups for adults ≥ 20 years of age, using 
NHANES 2003-2004 and Health Survey for England data. Unweighted samples were 
used. The data was stratified into two age groups (< 40 and ≥ 40 years) as above 40 
years there is an increased risk of developing diabetes. The sample of individuals < 
40 years who had diabetes was too small to predict the WC cutoff values for this 
group. The optimum cut points predicting diabetes among adults ≥ 40 years old was 
108.9 cm (42.9 in) for AA men and 104.6 cm (41.2 in) for AA women. In terms of 
BMI the cut points were 31.7 kg/m² for men and 27.7 kg/m² for women (14). 
Okosun et al., 1999 utilized the NHANES III data to assess the ability of the 
NCEP ATPIII WC cut points  of 102cm and 88 cm in predicting correctly 
dyslipidemia, type 2 diabetes, and hypertension in only overweight adults (BMI 25-
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29.9 kg/m²) who were 20-90 years of age. WC had been measured at midpoint 
between the rib and the top of the iliac crest. The other metabolic markers wer 
defined as: total cholesterol ≥240mg/dL; HDL< 35 mg/dL; LDL-C  ≥130 mg/dL; 
triglycerides  ≥ 200mg/dL; fasting blood glucose ≥ 126 mg/dl or use of hypoglycemic 
medication or insulin; a 2 hour post load oral glucose tolerance test >200 mg/dL; 
systolic blood pressure ≥ 140 and diastolic blood pressure  ≥90 or current use of anti-
hypertensive medication. The analyses were performed by age groups including 
young (17-39), middle age (40-59), and elderly (60-90years). Among AA men the 
sensitivity of the 102 cm was only elevated for the LDL (46-80), and lower for the 
other metabolic risk (20-<40). However, sensitivity tended to increase with age. 
Given the low sensitivity of the WC measures, the study recommends further studies 
to determine the specific WC cut-points by ethnic group (15). 
Another study from Okosun et al., 2000 examined the abdominal fat or WC 
values associated with the established BMI cut off points for overweight and obesity 
among individuals 17-90 years, using NHANES III data. Linear regression analysis 
was carried out to estimate the gender and ethnic specific WC corresp nding to 25-
29.9kg/m² and ≥ 30 kg/m², also a ROC curve technique was run to determine WC 
corresponding to BMI cutoff values specified above.   The results showthat AA men 
had similar BMI and mean weight compared to EA, but AA women had significantly 
higher BMI and mean body weight than their EA counterparts.  AA men and women 
had lower WC values at given levels of overweight and obesity. For the overweight 
individuals, the authors recommended the WC of 86-87 cm and 91-92 cm, 
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respectively, in women and men. The analogous values for obesity were 97 cm for 
women and 101-103 cm for men (17).  
Zhu et al., 2005 assessed the WC cut off values for identifying one or more of 
the three cardiovascular disease risk factors in different ethnic groups based on 
NHANES III data. The risk factors were defined as high blood pressure SBP ≥ 140 
mmHg and DBP ≥ 90 mmHg or current use of anti-hypertensive medication; high 
plasma glucose > 125mg/dL or use of medication; dyslipidemia : Low HDL < 35 
mg/dL for men and < 45 mg/dL for women, and LDL concentrations ≥ 160 mg/dL or 
currently on hypercholesterolemia medications. The WC corresponding to 
conventional BMI of 18.5, 25, 30, 35, 40 kg/m² with one or more CVD were similar 
in AA, EA and Mexican American women and were 70, 83, 94, 104, and 115 cm 
respectively. The equivalent values in men varied among different ethnic groups. The 
WC cut offs were 5-6 cm higher for EA than for AA at every BMI level between 25-
40 kg/m². The authors also estimated the WC corresponding to 25 and 30 kg/m² when 
one or more Metabolic syndrome parameters were present. Among overweight AA, 
the WC were 86 cm for men and 83 cm for women, while for obese individuals the 
estimated WC were 97 cm for men and 91 cm for women (16).  
Based on the above studies, some age categories and/or non-overweight or 
obese individuals with high WC and increased MetS risk were excluded from the 
analysis. There is need to identify WC on the basis of their empirical relation with 
obesity related metabolic risk factors, rather than WC values that identify cut off 
values corresponding to BMI from Europid populations. Additionally, in both females 
and males, WC increases with age largely due to gain in body weight and the WC are 
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also seen with aging in the absence of weight gain. As the age increases so do risk 
factors of chronic illnesses, thus, an assessment of the need for age specificWC 
cutoffs in adults will be carried out in consideration of disease risk factors. I propose 
to (1) investigate the sex specific optimal waist cut points which best identify 
individuals with metabolic abnormalities consistent with the metabolic syndrome 
among African Americans ≥ 20 years old independent of BMI cutoff values; (2) 
evaluate which WC cutoffs are appropriate among the different cutoff points, 
including those proposed by the NCEP and IDF; (3) determine the gender specific 
cutoff values of BMI in relation to multiple metabolic risk factors among African 
Americans; (4) identify the threshold values for waist circumference and BMI by ten-
year age groups (20-29; 30-39; 40-49; 50-59; 60-69; and 70+). (5) Compare the 
discriminate gender specific cut off values of WC and BMI for detecting metabolic 
risk factors between cases with and without elevated blood pressure.  Raised blood 
pressure is the most common component of the MetS among AA. We will assess if 




2.4.1. Body Mass Index Categories 
Excessive body fat, overweight and obesity are associated with increased 
mortality and morbidity (166). In the absence of simple methods to measure total 
body fat, the assessment and classification of overweight and obesity are dependent 
on practical definitions that have been established based on body mass index or 
Quetelet’s Index which relates weight to height (weight/(kg)/height (m²). As there are 
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no established cut-off points for fat mass or % body fat to translate into cut-offs for 
BMI, The WHO Expert Committee (167) and the 1997 WHO Expert Consultation 
(161) reports led to the classification of the categories of BMI (Table).  
 
CLASSIFICATION OF BMI 








































Sources: WHO 1995, WHO, 2000 and WHO 2004. 
The WHO recommends international use of the BMI cut-offs with awareness 
that the health risk at a given BMI would vary in association with body build and 
proportions, also within and across populations (161).  Moreover,  BMI cut-off points 
should be interpreted in combination with other morbidity and mortality risk factors 
(HTN, serum lipids, impaired glucose metabolism, type of fat distribution, smoking, 
disease etc…) (167) to limit the misclassification due to non-similar contributions of 
bone mass, muscle mass, and fluid to body weight (168).  
The rationale behind the BMI definitions is based upon epidemiological data 
that shows increased mortality with BMI above 25 kg/m² (167,169-172). The increase 
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in mortality, however, appears modest until a BMI of 30 kg/m² is attained.  
Individuals with a BMI of ≥ 30 kg/m² have a mortality rate from all causes, and CVD 
in particular, 50-100 percent above those with normal range of BMI – 20-25 kg/m² 
(167,171). These cut points were derived primarily in European populations to 
correspond to risk thresholds for a wide range of chronic diseases and mortality (173) 
and there has been ongoing debate as to whether these criteria for obesity and 
overweight are appropriate for non-European populations as they do not account for 
difference in body fat distribution, and the relation of body size and composition with 
health outcomes (25). 
Some of the concerns have been that the cutoff points for overweight and 
obesity considerably underestimate obesity related health issues among Asia  
populations and might overestimate risk in pacific populations (79), consequently the 
BMI should be lowered for Asian, and BMI standards should be higher for the Pacific 
Island populations (Samoa) than those recommended by WHO (174). In 2000, the 
International Association for the Study of Obesity (IASO), the International Obesity 
Task Force (IOFT), and the WHO proposed the cutoff points of 23 to 24.9 kg/m² for 
being overweight and ≥25.0 kg/m² for obesity in adult Asians (175).  In 2002, the 
WHO expert consultation reported lack of universal BMI values for overweight and 
obese in all Asian populations. In an addition to the established cut-off points WHO, 
the expert committee provided  in 2002  new cut-off points of ≥23 kg/m² as increased 
risk and ≥ 27.5 kg/m² for high risk thresholds for public health intervention. (79).   
 Among African Americans, available cohort studies state that adiposity may 
be a less important predictor of mortality among AA than among EA, especially 
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among women. In individuals who never smoked and without history of disease, the 
association between  a high BMI  and elevated risk of death was observed to be more 
moderate among AA men and  women, a small increase in risk of death was found 
only at BMI 35.0 or higher (176). Two large U.S. surveys – the NHANES and the 
NHIS showed that the BMI-related to increased mortality begins at a 1 to 3 kg/m² 
higher BMI level among African Americans than among European Americans. The 
BMI associated with minimum mortality was 26.8 kg/m² for AA women and 27.1 
kg/m² for AA men compared to 24.3 kg/m² and 24.8 kg/m² in EA women and men 
respectively (177). Among African American women, high BMI has been suggeted 
to be less hazardous to health (WHO 1995- 3) and central obesity may be less 
strongly associated with CVD and DM risk factors among AA women compare to EA 
(167). 
 
2.4.2. BMI and Aging 
Longitudinal studies have demonstrated the association of body fat gain with age 
across cohorts with different age ranges. In general, the average BMI increase was 
largest in the younger subjects and African American women (mean age 29 years). 
This increase of BMI throughout the greater part of adulthood was related to the 
increase in both muscle mass and body fat (3).  In the Coronary Artery Risk 
Development in Young Adults study of a young cohort (18-30 years), the average 
increase in BMI over 10 years period was 2-4kg/m² (178). Among African Americans 
males and females, the increase was 3.2 kg/m² and 4.1 kg/m², respectively. 
Corresponding BMI increase among European Americans were 2.3 kg/m² in males 
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and 2.4 kg/m² in females. In the Atherosclerosis in Communities study, the middle 
aged 45-64 years group had a BMI increase on average 1kg/m² and was larger in the 
younger participants after 9 years of follow up (179).  
 BMI appears to increase with age until the 70 years of age and then is reversed at 
older age (180).  At older age, the changes in BMI are associated with the decrease in 
muscle mass, and fat mass is often increasing (181). Other studies have shown a 
decline in size of adipose depots with aging probably due to the reduced capacity of 
pre-adipocytes to mature. This is accompanied by accumulation of fat outside adipose 
tissue such as in muscles, liver and other sites possibly leading to the dysfunction of 















CHAPTER 3:  RESEARCH DESIGN AND METHODS 
3.1. Survey Description and Sample Design  
The National Health and Nutrition Examination Surveys (NHANES) program 
produces health and nutritional data on children and adults in the United States.  The 
program was initiated in 1960s by the National Center for Health Statistics (NCHS), 
which is part of the Centers for Disease Control and Prevention (CDC). Since early 
1960s NHANES has conducted a series of periodic surveys, however, in 1999, the 
program was designed to become a continuous annual survey with evolving focus to 
address emerging health and nutritional needs.  The NHANES uses complex, 
stratified, multi-stage, clustered samples of civilian, non-institutional zed populations. 
Yearly, a nationally representative sample of about 7,000 individuals of all ages is 
selected in households across the United States. African Americans, Mexican 
Americans, adolescents aged 12-19 years, and persons aged ≥ 60 years are 
oversampled to generate more precise estimates for these groups. A detailed 
description of design specifications can be obtained elsewhere (182). 
The survey consists of an interview in the household followed by a clinical 
examination in a mobile examination center (MEC).  The NHANES questionnaires 
are administered using Computer Assisted Personal Interviewing (CAPI) and the 
Audio Computerized Self-Administered (A-CASI). The questions include 
demographic, socioeconomic, dietary, and health-related questions. At the completion 
of data collection, the interview data files are transmitted electronically to a central 
survey database system. In mobile examination center, the examinations are 
conducted by a physician and other highly trained medical personnel. The medical 
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tests include physical examination, blood and urinary laboratory tests, X-rays, and 
other health measurements and interviews. Detailed information on administering 
questionnaires, examination instructions, specimen collection and processing, and 
quality control systems are discussed in the Survey Operations Manuals and Consent 
Documents (183-186). NHANES studies undergo institutional review board approval 
and the respondents sign a Household Interview Consent form prior to the start of the 
interview. Other Consent/Assent and Parental Permission for the Examination at the 
Mobile Exam Center and for Specimen Storage and Continuing Studies are 
completed by participants as well.  
 
3.2. Data Availability and Use of Sample Weights 
The NHANES datasets and related documentations are available on the 
following website http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm and 
were downloaded for analysis. Data are released in two year cycles described as 
NHANES 1999-2000, NHANES 2001-2002, NHANES 2003-2004 etc, and in 
component-specific data files. For the analysis of data, 4 year cycles of the 
continuous NHANES were combined, hence increasing the sample size and analytic 
options. Variables included in this study were extracted from the demographics, 
examination, laboratory, and questionnaire data files. The variables were select d 
based on the waist circumference/BMI association with the metabolic abnormalities 
as already discussed in detail in the literature review section. The sequenc  or 
identification numbers allowed the extraction of variables of interest from each of the 
data files and were merged to form the final data set. The variables include age, 
gender, poverty income ratio, WC, BMI, MetS components, dietary variables, hepatic 
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markers for nonalcoholic fatty liver disease, C - reactive protein and prothrombotic 
state, microalbuminuria, and hyperuricemia. 
During sampling, each participant did not have the same probability of 
selection; there was large oversampling of adolescents aged 12-19 years, African
Americans, Mexican Americans, low income European Americans and older persons 
(187). Because of the complex multi-stage probability sample design, the sample 
weights were applied in data analysis to produce unbiased population estimates (188).  
These sample weights can be considered as measures of the number of persons the 
particular sample observations represent in the population. They also reflect the 
differential probabilities of selection and the adjustment for non-response and post-
stratification to match the 2000 U.S. Census population (187).  
Additional aspects of the design that were taken into consideration in data 
analyses are the strata and primary sampling units (PSUs) pairings from the sample 
design. The strata were defined by geography and proportions of minority populations 
and most strata contain two PSUs.  The primary sampling units were normally single 
counties, with small counties combined to meet a minimum population size. The 
PSUs were further divided into segments and a sample of households and individuals 
are randomly drawn within each segment (Figure 5). The strata and PSU represent the 
sampling units and were used to produce unbiased variance and sampling error 
estimates (214). Currently, the National Center for Health Statistics (NCHS) 
recommends the utilization of the Taylor Series Linearization methods (TSL)to 
estimate variance in all NHANES surveys.  Statistical software packages for instance 
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STATA, SAS, SPSS and SUDAAN can all be utilized to estimate the variance by 
TSL methods (189).  




3.3. Statistical Analysis  
3.3.1. Statistical Software Package 
SAS 9.2 software was used to prepare data for analysis, including sorting, 
extracting, merging, and assumptions testing of the data. STATA 10.1 or 11.1 
versions were also utilized in data analysis and have advanced tools to manage 






3.3.2. Study Sample 
A Nationally representative cross-sectional sample of 4415 adults African 
Americans civilian ≥ 20 y were selected from the NHANES 1999-2006 data. 
Participants with at least one missing parameter in anthropometric, blood pressure or 
metabolic criteria measurements were excluded from all analyses. Subjects who 
would have fasted less than 8 hours prior to blood tests were not included in the 
analysis. Pregnant as well as subjects with cancer were also excluded during data 
analysis. 
3.3.3. Variables 
Definition of multiple metabolic risk factors 
In order to determine the WC/BMI among African Americans, participants 
with two or more of the four NCEP-ATP III metabolic syndrome criteria were 
defined as having multiple risk factors. The criteria include hyperglycemia (fasting 
blood glucose ≥ 100 mg/dL or use of hypoglycemic medication); dyslipidemia 
(Triglycerides ≥ 150 mg/dL, HDL-cholesterol < 40 mg/dL for men and < 50mg/dL 
for women, or current antidyslipidemia medication), and high blood pressure (SBP ≥ 
130 mmHg and or DBP ≥ 85 mmHg, or use of antihypertensive medication).  We 
considered the presence of multiple MetS risk factors as an outcome variable of the 
ROC analysis to obtain waist circumference cutoffs.   
Anthropometric, laboratory measurements, and body composition 
The NHANES weight, height were captured electronically from the measuring 
instruments to minimize possible data entry errors. Experienced trainers and 
observers monitored technician performance in the field. Standards procedures that 
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were followed for the anthropometric measurements have been reported in the 
Anthropometry Procedures Manual and the Anthropometric Standardization 
Reference manual (183).  Body mass index was calculated using the weight (kg) 
divided by the square of height (m²). Abdominal obesity (WC) was measured to the 
nearest 0.1 cm using a steel measuring tape at the high point of the iliac crest during 
minimal respiration. Up to four blood pressure readings were measured using a 
standard mercury sphygmomanometer, with a subject sitting on a chair after at least a 
five-minute rest. For participants with three or four readings, the average of th  last 
two was used to establish the blood pressure status.  The reported average was used in 
this analysis. When only two measurements were taken, the last one was used.  
 Details of the laboratory procedures for MetS components are discussed 
elsewhere (190). Fasting blood glucose concentration was quantified using an 
enzymatic reaction. HDL-C was estimated after the precipitation of otherlipop oteins 
using a heparin-manganese chloride mixture. Serum triglyceride levels were 
measured enzymatically after hydrolyzation to glycerol. C reactive protein 
concentrations were measured by latex-enhanced nephelometry on a BN II 
nephelometer (Dade Behring Inc., Deerfield IL). 
The whole-body DEXA scans were obtained using a Hologic QDR 4500A 
fan-beam densitometer (Hologic Inc, Bedford, MA). Pregnant subjects were excluded 
from scanning. A number of participants had missing valid DXA data related to 
implants (pacemakers, stents, breast augmentation and hip replacements) and higher 
BMI levels.  DXA scanner cannot penetrate much thicker than 15 cm adiposity and 
some of the implants would have been appeared as dense bone and additional lean 
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soft tissues. Because data were not missing at random DXA missing values were 
estimated. Multiple imputations (M=5) were performed using equential regression 
multivariate imputation within 10 age-by-sex groups. 
Supplemental Analysis Variables 
Supplementary analysis was carried out to compare individuals with presence of 
MetS and those without MetS in terms of dietary, serum nutrients, socio-economic, 
lifestyle factors, inflammation and thrombotic markers, hyperuricemia, 
microalbuminuria, hepatic biomarkers related to nonalcoholic fatty liver disase 
(NAFLD). 
Dietary Variables  
Dietary and lifestyle variables related to the WC and BMI was considered. These 
include total Kcal, fat/saturated fat, carbohydrate, protein, fiber, and antioxidants (vit 
C, carotene, vit E, and selenium). Lifestyle factors included physical activity, alcohol, 
and cigarette intake. Studies have suggested that the accumulation of excessive body 
fat has been associated with increased oxidative stress, a potential early instigator of 
obesity associated metabolic syndrome (217). Thus, nutrition biochemistries of 
antioxidants namely serum vitamin C, carotene, vitamin E, selenium were also 
utilized during analysis and compared among individuals with and without MetS.  
Socio Economic Variables 
To assess the socio-economic status of a family, poverty income ratio (PIR), 
education, and marital status variables were utilized. PIR values for NHANES 
participants were computed using the family income divide by the family’s 
appropriate poverty threshold (US Census Bureau, 2007). A PIR value of less than 
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1.0 is below the official poverty threshold while the PIR of ≥ 1.00 indicate income 
above the poverty level.  
HEPATIC MARKERS FOR NAFLD: In the general population, all MetS 
components have been shown to correlate with fatty liver, a characteristic of the 
nonalcoholic fatty liver disease (NAFLD) (50). The latter has been called the hepatic 
component of MS (192-194). Most cases with NAFLD present with an elevated 
alanine aminotransferase (ALT) enzyme activity, thus ALT is used as a marker of 
NAFLD (195). Recent studies have also indicated that gamma-glutamyl transferase 
(GGT) is also associated with NAFLD, and ALT, GGT, and alkaline phosphatase 
(AP) are strongly correlated to the prevalence of the MetS (194,195). The stronge 
contributors for the association of MetS with hepatic enzymes have been shown to be 
central obesity, elevated triglycerides and fasting glucose. For AP, low HDL –
cholesterol concentrations have been found with significant impact (197). The level 
of ALT, GGT and AP enzymes were assessed in the study. 
C-REACTIVE PROTEIN:  is one of the measures of the body’s response to 
inflammation from chronic conditions such as arthritis, and environmental exposure 
to agents such as tobacco smoke. Also, the CRP reflects the acute phase response to 
an infectious disease or other causes of tissue damage and inflammation. Cytokines 
generated by inflammatory cells enter the systemic circulation where they stimulate 
the liver to release C - reactive protein. Levels of the inflammatory marker CPR are 
increased in subjects with MetS, and are associated with the individual components of 
the MetS (198). Studies have shown that AAs have higher levels of CRP than EA. 
The CRP levels have been shown higher in AA women than AA men, EA men and 
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women with a median CRP of 3.5 vs. 2.1, 3.2 and 1.7 mg/l, respectively (199). The 
significance was p <0.001 for each comparison to AA women. 
PROTHROMBOTIC STATE: An increase in plasminogen activator inhibitor-1 and 
coagulation factors, referred to as a prothrombotic state, tends to occur more 
frequently in AAs. Fibrinogen is an essential blood-clotting factor and is also 
involved in other functions including smooth muscle proliferation and platelet 
aggregation. It is emerging as an important risk factor for CVD and this measure was 
included to assess its association with MetS syndrome. Fibrinogen levels have been 
found to be higher among African Americans than EA, particularly in subjects with a 
family history of diabetes and CHD (200,201). However, fibrinolysis levels have 
been found to be enhanced in African Americans (200) as well.  In the NHANES data 
fibrinogen values are available for participants aged 40 years and older.  
MICROALBUMINURIA: reflects transvascular albumin leakage related to 
abnormalities of endothelial function (202). Microalbuminuria has been linked to a 
great risk for future CVD and mortality, atherosclerosis, renal disease, and all-causes 
of mortality (203). Several studies have disclosed that MetS is independently 
associated with an increased risk for chronic kidney disease and microalbuminuria 
(204,205). The prevalence of microalbuminuria increases with the number of 
components of MetS, and particularly high plasma glucose, high blood pressure and 
obesity have been shown to be the major risk factors for microalbuminuria (203). The 
inclusion of microalbuminuria as part of MetS has been suggested in some studies 




HYPERURICEMIA:  It has been suggested as a simple marker of the metabolic 
syndrome (207,209), and the serum urate increases with the number of components of 
the MetS condition. Insulin resistance has been noted to induce the low excretion type 
hyperuricemia (210) thus; the reduced renal excretion of urate among patients with 
the metabolic syndrome may explain the increased frequency of hperuricemia. 
Additionally, studies have shown that visceral fat accumulation has been found to 
cause the hyper synthetic type hyperuricemia through elevated fatty acid influx into 
the liver (211,212).  
3.3.4. Data Analysis 
The distribution and normality of continuous variables was assessed and 
necessary variable transformation applied. Basic descriptive statistics including mean 
values for general characteristics, anthropometric profiles, body composition values, 
and the 5 components of MetS were estimated by gender and age groups. Age was 
grouped by ten year age categories starting from 20-29, and for older adults age in 
years was top coded at ≥ 70 years of age. The age grouping was related to differences 
in absolute increase in WC and BMI in the population (149).  To assess differences in 
the weighted values of means and frequencies between women and men, and 
individuals with and without MetS, student’s t-test and Rao-Scott chi-square test wer  
carried out. 
 The receiver operator characteristics (ROC) curve analysis was used to 
determine cutoff points of WC/BMI by gender and by ten-year age groups 
corresponding to; (i) whether participants have individual or ≥ 2 MetS risk factors 
defined by NCEP-ATPIII (except for WC) such as high blood pressure, 
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hyperglycaemia, raised triglycerides, and low HDL-cholesterol; and (ii) whether 
participants stratified by high blood pressure status ( raise BP : SBP≥ 130 mmHg 
and/or DBP ≥ 85 mmHg and non-raised BP) have ≥ 2 MetS risk factors. ROC 
analysis was also used, in addition to simple regression, to identify WC values 
corresponding to the determined BMI cut-off values in comparison with WHO 
overweight (25 kg/m²) and obesity (30 kg/m²) thresholds in both men and women.  
The methods to identify optimum cutoff points of WC/BMI using sensitivity, 
specificity, and the ROC curves were applied. These methods include the distance 
from the upper left corner of the point on the ROC curve [(1-Sensitivity)² + (1-
Specificity)²] and the value of the Youden index (sensitivity + specificity-1) ( 
213,214). Furthermore, other measures of diagnostic accuracy, such as the positive 
predicted value (PPV), the negative predicted value (NPV), the total accuracy, and 
the ROC curve area were considered. The above enumerated measures of accuracy
can be defined as follows. Sensitivity and specificity for given cutoffs are the 
probabilities of correctly identifying cases with a certain condition (or disease) and 
true non-cases that do not present the condition (or illness) respectively. PPV isthe 
proportion of those with the condition among all individuals the test classified as 
positive, while the NPV is the proportion of true non-cases among individuals 
without the condition. The total accuracy is the sum of true cases plus non cases 
accurately predicted by the tests expressed as a percentage of the total sample (213).   
A measure of WC/BMI with maximum sensitivity and specificity, which 
shows the minimum distance from the upper left corner of the ROC curve and the 
maximum Youden index, correspond to the optimal cutoff points (2212-214).  In the 
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case of a WC with higher sensitivity and NPV, it was selected over another measure 
with higher specificity when both measures have the same total accuracy. The area 
under the ROC curve (AUC) was used as a measure of the overall accuracy of 
performance of the ROC curve and to examine the predictive value of WC/BMI for 
MetS components. The AUC takes values between 0 and 1, where an AUC of 1 is a 
perfect screen test. The null hypothesis that the AUC is equal to 0.5, which represents 
a test equal to chance, will be tested.  The additional AUC values of ≥ 0.7 but < 0.8, ≥ 
0.8 but <0.9, and ≥ 0.9 have been suggested as reflecting the acceptable, excellent, 
and outstanding levels of discrimination (216). Statistical tests for a comparison of 
AUCs within gender and all pairs of age groups was performed by the t-test and p 
value < 0.05 will be considered statistically significant. The measures of diagnostic 
accuracy from the study was compared with existing WC values such as the NCEP,
IDF and previous studies (13,17).  
Furthermore, weighted means of MetS criteria, weighted proportions of 
subjects with abdominal obesity and overall obesity, and weighted prevalence of 
MetS were estimated using the proposed optimal cutoff values of WC/BMI and were 
compared with the existing cutoff values from NCEP, IDF and WHO. T-test was 
applied to compare continuous variables, and chi-square test assessed the differences 
in categorical variables. Statistical significance was set at p value< 0.05 for the t-test 
and chi-square tests. 
Logistic regression analyses was applied to estimate gender specific odd ratio 
of having MetS risk factors versus not having the risk factors for the estimated WC 
and BMI, controlling for covariates such as age, education, poverty-income ratio, 
55 
 
diet, physical activity, smoking, alcohol consumption, CRP and menopausal status. 
The WC and BMI reference values were set as the value below the estimated WC and 
BMI in question 3.1.  Gender – specific and weighted Pearson correlation were run 
between each pair of the BMI/WC, and body composition (fat and fat free mass)
variables and MetS components adjusting for age and anthropometric measures as 
appropriate. Multiple regression analysis was used to examine the possible variables 
that contribute to the variation in BMI.  Variables with ≥ 10% missing data were 
eliminated before running the regression analysis. Logistic regression was performed 
to assess whether there are significantly differences among AA men/women with and 
without MetS with respect to the selected predictors of MetS. 
Statistical differences in environmental and health determinants that may 
contribute to MetS among AA adults were assessed when comparing individuals with 
and without metabolic syndrome. Unless otherwise mentioned, the appropriate 
sample weights, stratum variable and primary sampling unit (PSU) variable were 











Chapter 4: RESULTS 
PAPER 1: NEW WAIST CIRCUMFERENCE CUT-OFFS FOR AFRICAN 
AMERICANS ACCORDING TO THE CLUSTERING OF METABOLIC SYNDROME 
RISK FACTORS, NHANES 1999-2006 
 
Abstract 
Background: Although central obesity is highly associated with metabolic syndrome 
criteria, reliable cutoff values for waist circumference independent of BMI1 are still 
lacking among African Americans. 
Objective: The objective was to determine the gender specific cut-off values of waist 
circumference (WC)2 for screening African Americans, which optimally predict the 
clustering of two or more metabolic syndrome risk factors. 
Methods: The study consisted of 2136 females and 1908 males African American 
participants in the NHANES3 (1999-2006) study. The metabolic syndrome 
components were defined according to the NCEP/ATPIII4 criteria.  The WC values 
for detecting the gender specific metabolic risk factors were t sted using receiver 
operating characteristics analysis (ROC)5. The Youden Index and the minimum 
distance values from the upper left corner of the ROC curve were calculated to 
determine the WC thresholds with an optimal combination of sensitivity and 
specificity. 
Results: The mean age of subjects was 46 years ranging between 20-85 years with a 
BMI of 29.9 (SE=7.4), in the range of 15.8-67.3 kg/m², and a WC of 98.5 (SE=16.9), 
                                                
1 BMI- Body Mass Index 
2 WC- Waist Circumference 
3 NHANES: National Health and Nutrition Examination Survey (NHANES) 
4 NCEP/ATIII-National cholesterol Education Program/Adult Treatment Panel III. 
5 ROC-Receiver Operating Characteristics 
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in the range of 60.4-163.1cm. The WC cut-off values were 94.7 cm with 76 
sensitivity and 67 specificity for males and 97.6 cm with 70 sensitivity and 61 
specificity for females. These WC cutoff values did not differ substantially by age 
categories. 
Conclusion: For the early detection and management of the metabolic syndrome in 
African Americans, the WC of 95 cm for males and 98 cm for femal s are suggested 
as appropriate cut-off values to identify central obesity. 
  
Introduction 
Metabolic syndrome (MetS)6 is comprised of multiple risk factors that include 
hyperglycemia, hypertension, abnormal fat distribution, low HDL7 cholesterol, and 
high triglyceride levels. These criteria have been related to insulin resistance and 
visceral adiposity. Individuals with MetS are considered to have high risk for type 2 
diabetes and cardiovascular diseases (29,218). The MetS criteria have been defined 
by WHO, and other groups such as National Cholesterol Education Program-Adults 
Treatment Panel III (NCEP-ATPIII) and (IDF)8 (2,4,29,218). There are differences in 
how IDF and NCEP-ATPIII diagnose central obesity, measured as w ist 
circumference (WC) (Table 1). With regard to WC, the NCEP-ATPIII definition 
does not take into account ethnic differences, thus the heterogeneity of abdominal 
obesity and its association with metabolic risk factors. The WC threshold criteria, 
chosen by NCEP-ATPIII and IDF for the diagnosis of abdominal obesity, are based 
on the study of Lean et al. (1995), which related WC to BMI in a European 
                                                
6 MetS- Metabolic Syndrome 
7 HDL- High Density Lipoprotein 
8 IDF- International Diabetes Federation 
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population (8). Current National Institutes of Health guidelines suggest that for any 
body mass index (BMI) category, normal to obese, the presence of a WC ≥ 102 cm 
for men and ≥ 88 cm for women is indicative of a greater risk for cardiovascular and 
metabolic diseases than lower WC values (64).  
Central adiposity is recognized to be highly associated with increased risk of 
cardiovascular disease, the presence of hypertension, dyslipidemia, and type 2 
diabetes independent of overall obesity (3,4). A WC cutoff value based on the 
relationship of WC to BMI has not been shown to be an optimal method of 
identifying the pathological effect of central obesity (6). Successful prevention and 
management of increasing metabolic abnormalities and related crdiovascular and 
type 2 diabetes illnesses require accurate identification of high-risk individuals based 
on their unique risk factors. In response to this need, IDF and certain Asian 
populations have defined central obesity thresholds based on ethnic differences (6). In 
acknowledging insufficient information on best WC cutoffs that predict risk in 
African Americans, IDF recommends that people of African descent use the 
European values until more specific data are available (218).   
Previous studies on WC cut off points in African Americans were limited and 
either lacked sufficient sample size or used convenience samples. In addition, some 
were not inclusive of the clustering of NCEP-ATPIII MetS abnormalities (13-17) and 
depended on existing values of WC corresponding to BMI cutoffs, which mig t not 
be optimal for the African Americans (8). The inconsistent results among African 
Americans have provided varied optimal cutoff points of waist circumference that 
range from 89.0-108.9 cm for men and 83.0-104.6 cm for women (7). Given the 
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paucity of existing data, more reliable cutoff values for WC in African Americans 
need to be proposed independent of existing BMI categories.  
The present study used a large and nationally representative sample of African 
American adults to: (1) determine optimal cutoff points of waist circumference for 
detecting the individual and cluster of metabolic risk factors by gender a age group; 
(2) ascertain which waist circumference thresholds are appropriate among varied 
values including those recommended by NCEP and IDF; (3) compare the gender 
specific cutoff values of WC for detecting metabolic risk factors between cases with 
and without raised blood pressure.    
 
Methods and Procedures  
Subjects 
This study analyzed data on African American subjects from the NHANES 
1999-2006, who participated in both interview and clinical examination in a mobile 
examination center (MEC). The NHANES uses complex, stratified, multi-stage, 
clustered samples of civilian non-institutionalized populations (219).  A total of 4044 
subjects (2136 women and 1908 men) aged ≥ 20 years were studied. Pregnant, 
lactating women, individuals using insulin and with missing values were excluded 
from the study. In addition, subjects who had fasted less than 8 hours prior to blood 
tests or who had cancer were excluded during data analysis. Of the 4044 subjects, 
data were collected on 1445 participants (males and females) for all f the NCEP 
ATPIII criteria and these subjects were therefore eligible for the ROC analysis. 
Detailed description of institutional review board approval, design specifications, 
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survey operations manuals and consent documents for NHANES can be obtained 
elsewhere (183-184).  
Anthropometric measurements and blood pressure monitoring 
With an electronic scale, weight was measured in pounds and converted to 
kilograms in the automated system. Height was measured with a fixed stadiometer to 
the nearest 0.1 cm. The WC was evaluated with a measurement of the abdominal 
circumference at the high point of the iliac crest. The measurement was recorded to 
the nearest 0.1 millimeter using a measuring steel tape around the trunk at the end of 
a normal expiration (body measure link). BMI was calculated as weight (kg) divided 
by the square of height (m²). Systolic and diastolic blood pressure readings were 
recorded four times using a standard mercury sphygmomanometer, with subjects 
sitting on a chair after at least a five-minute rest. For participations with three or four 
readings, the average of the last two was estimated and used in this analysis. In case 
of two measurements, the last reading was considered as the verage. When only one 
blood pressure reading was available, that reading served as the average (221). 
 Blood Examination 
For fasting blood glucose and triglycerides, data were collected on a 
subsample of the 4044 of participants. This subsample is nationally representative and 
corresponding sample weights were estimated to reflect this stage of sampling and the 
no response. For the determination of WC and BMI thresholds, the subsample and its 
relative sample weights were used in the analysis. 
The biochemical measurements were obtained at the mobile examination 
center and blood glucose concentration was quantified using a hexokinase enzymatic 
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reaction (223).  The serum concentration of HDL cholesterol (Heparin-Mn+² method 
and direct method) and triglycerides (Enzymatic reactions) werem asured using an 
Hitachi 704 Analyzer (Roche Diagnostics, Indianapolis, IN) (224). 
Definition of multiple cardiovascular risk factors to obtain WC cutoffs 
Several studies have suggested that WC may be a better anthropometric 
predictor of many MetS risk factors, which aggregate in an individual, compared to 
BMI or waist hip ratio (5,225). For this study, multiple metabolic syndrome 
abnormalities were defined as the occurrence of two or more of the following criteria: 
1) fasting blood glucose values ≥ 100 mg/dL or the use hypoglycemic agents; 2) high 
concentrations of serum triglycerides (≥150 mg/dL) or treatment for this lipid 
abnormality as alternative indicator; 3) high blood pressure (systolic ≥ 130 mmHg, 
diastolic ≥ 85 mmHg, or the use of antihypertensive medications); and 4) low 
concentration of serum HDL < 40 mg/dL for males and < 50 mg/dL for females or 
drug treatment for reduced HDL. The presence of at least two of these multiple risk 




Data were analyzed using SAS 9.2 and STATA software to account for the 
complex survey design and incorporate cluster, strata and sample weights in the 
analysis. SAS statistical software (release 9.2) was used for data cle ning and 
computation of descriptive statistics for the general characteristics, the 
anthropometrics, and MetS risk factors. The data are presented as means (± S.E.) and 
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percentages for categorical variables. T-test and Rao Chi-square test wr  applied to 
compare males and females. The statistical significance was considered at P <0.05. 
Continuous variables not normally distributed were transformed and geometric means 
were used for the means of serum triglycerides, HDL, and systolic blood pressure 
because of their right skew distribution.   
ROC  analysis was performed using STATA 10.1 for Windows (STATA, 
College Station, TX) to find appropriate gender specific WC cutoff values for 
detecting the individual and the clustering of ≥ 2 metabolic syndrome risk factors 
defined by NCEP-ATPIII (except for WC). The sensitivity and specific were 
estimated at each 1 cm increment of WC. The models were reanalyzed with age 
(categorized by 10-year age groups) and by hypertension status adjustments (raised 
BP: SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg and non-raised BP). We defined the 
best cut off values of WC with the optimal combination of sensitivity and specificity 
based on the maximum Youden’s index (sensitivity + specificity -1) (214) and the 
minimum distance from the upper left corner of the point on the ROC curve [(1-
sensitivity)² + (1-specificity)²].  Additional measures of diagnostic accuracy such as 
total accuracy, positive predictive value, negative predictive value, and ROC curve 
area were also calculated. A WC with higher sensitivity and negative predictive value 
(NPV) was selected over a WC with higher specificity when both values had identical 
total accuracy.  The areas under the ROC curves were calculated to assess the overall 
accuracy of performance of the ROC curve and to determine the ability of WC to 
predict the presence of the cluster of MetS indicators. The measures of diagnostic 
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accuracy (AUC) from the newly estimated WC were compared with those of existing 
WC values from NCEP, IDF and previous studies (15). 
Results 
Participant characteristics  
Subjects characteristics are provided in Table 2. The average age of the 
subjects was 42.9 years (± 0.43; range: 20-85) for females and 41.8 years (± 0.42; 
range: 20-85) for males. The distribution of age groups shows a higher proportion of 
individuals between 20-29 and 40-49 years of age, 22% and 23% respectively. At the 
youngest age range, more males (21%) than females (16%) were observed while the 
opposite was observed after 70 year of age (9% males vs.13% females). For the other 
age groups 30-39 y, 50-59 y and 60-69 y, the proportion of participants was 14%, 
16%, and 19%, respectively.  
Consistent with known gender differences, males had higher weight, height, 
SBP and DBP, compared with female participants. BMI and WC were significantly 
lower in males than in females. The TG was statistically significant different between 
males and females (T value=4.06, P < 0.001). The geometric mean for males for TG 
was 100.5 mg/dL (SE=2.437) with a confidence interval ranging from 95.8 to 105.5 
mg/dL.  The corresponding values for females were 86.5 mg/dL (SE=2.168) with a 
confidence interval of 82.3-91.0 mg/dL. The HDL geometric mean was 49.9 mg/dL 
(SE=0.451) with a CI of 49.0-50.8 mg/dL. Females had a significantly higher (T 




28-31% of the subjects did not have an abnormal MetS risk factor. At least two 
abnormal indicators of the MetS were present in 39% for males and 41% for females. 
The prevalence of MetS criteria and the number of risk factors were not sigificantly 
different between males and females (Table 2).  
The frequency of MetS criteria by gender and age categories 
The assessment of the prevalence of each individual criterion by gender 
revealed that high blood pressure was the most frequent risk factor, being presentin 
46.9 and 47.3% for females and males, respectively (Figure 1).  Low HDL 
cholesterol was present in 34% of the females compared to 23% of the males. High 
fasting blood glucose was almost equally present in males and females (31.2 & 
32.6%). The lowest frequency was observed for high triglycerides (11.9-19.4%). The 
frequency of the individual criteria was statistically significantly different between 
male and female subjects except for high fasting blood glucose (≥100 mg/dL) and 
high blood pressure (≥ 130/85 mm HG). 
Figure 2 portrays the prevalence of at least 2 metabolic risk factors (except 
WC) across age categories and by gender. The risk factors include elevatd blood 
pressure, triglycerides, fasting blood glucose, and low HDL levels. Males and 
females, 40-49 and 60-69 years of age, had the highest prevalence of at least 2 risk 
factors (24% and 27%, respectively), while the younger  and the oldest groups had the 
lowest (7% and 15%) prevalence followed by the 50-59 year age categories (17%). 
The percentage of at least two of the metabolic components was higher in females 
compared to males between the age cluster of 50-59 and 60-69 years. The young age 
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categories of 20-29 and 30-39 years had a lower proportion of females vs. males with 
2 or more risk factors. 
The mean average for anthropometric and medical profiles by age categories 
The anthropometrics and medical examination profiles in Table 3 show a 
generalized and marked increase of the mean for all the MetS components between 
20 & the 60th decade in both males and females. However, a decline was observed in 
the seventh decade except for SBP and HDL, which were at their highest at ≥70 years 
of age. For the ≥70 year group, the SBP reached 147.9 for females vs. 143.1 mmHg 
for males. HDL was 65.1 and 54.4 mg/dL for females and males, respectively.  In 
terms of gender related differences, the average of the MetS risk factors were found 
to be higher in males than females with the exception of WC, BMI, and HDL. The 
gap difference disappeared after the 5th decade for TG and narrowed for WC. Among 
females, there was a mean increase of 5-6 kg after 20-29 yrs and a decrease of close 
to 4 kg after the 70th birthday. The change in weight was less pronounced in males (1-
3 kg increase after 20-29 year category). However, significant body weight loss was 
recorded after 70 years and above (7.5 kg). 
 
WC cut-offs points for the detection of high blood pressure, hyperglycemia, 
triglyceridemia and low HDL by gender 
The WC cut-off levels were determined by relating them to the individual 
MetS component.  Table 4 summarizes the sensitivity and specificity for each WC 
level for the identification of elevated blood pressure, high fasting blood glucose, 
raised triglycerides, HDL levels and the presence of at least 2 of those criteria. 
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In males, the optimal combination of sensitivity and specificity was at 95 cm 
for high blood pressure and fasting blood glucose, at 97 cm for raised triglycerides, 
and at 98 cm for low HDL. The values ranges between 95 and 98 cm, with an optimal 
cut-off value found at ~ 95 cm for the presence of at least 2 of the criteria. In females, 
the optimal combination of sensitivity and specificity were at 96 cm for high blood 
pressure, at 99 cm for fasting blood glucose and at 98 cm for high triglycerides and 
low HDL. The presence of at least 2 of the metabolic risk factors was identified at ~ 
98 cm. 
 
Appropriate waist circumference determination 
Based on the Youden Index and minimum distance from the upper left corner 
of the ROC curve, the male WC cut off value that best predicts two or more 
metabolic risk factors was 94.7 cm. At this WC, sensitivity and specificity rates were 
76 and 63 % respectively (Table 5). The 102 cm waist circumference currently in use 
for males had a sensitivity of 53% and specificity of 77% (Table 5 & figure 4). For 
females, the threshold associated with the optimal combination of sensitivity and 
specificity was 97.6 cm, corresponding to sensitivity and specificity values of 71 and 
62% (Table 5).  The current NCEP ATPIII WC cut point of 88 cm corresponds to a 
sensitivity and specificity of 91 and 37% (figure 4). Figure 3 represents the ROC 
curve for the newly estimated cut off values for both males and females. The ROC 
area for males was 0.74 with a confidence interval of 0.70-0.78 while for females, the 
ROC was 0.72 and a confidence interval is 0.68-0.76. AUC was not statistically 
significant between males and females (P=0.554). 
67 
 
Characteristics of participants by blood pressure status and their WC cutoffs 
Table 6 compares the characteristics of subjects with and without elevated 
blood pressure.  The mean age was significantly lower among people without raised 
blood pressure than those with raised blood pressure in both males and females. A 
lower percentage of young people 20-39 as well as those 50-59 years of age had 
raised blood pressure in both males and females. The proportion of people who had 
high blood pressure significantly decreased with age. The mean BMI and WC were 
significantly higher in participants with raised blood pressure than those without for 
both genders. The percentage of people who had the clustering of risk factors was 
also significantly higher among those with elevated blood pressure than those without 
high blood pressure in both males and females.  
Table 7 shows the comparison of WC cutoff values for predicting the selected 
cluster of MetS risk factors using ROC analysis between subjects with and without 
elevated blood pressure. WC thresholds for males with and without high blood 
pressure were 95 cm and 94.7 cm, respectively. Corresponding values among females 
were 99 cm and 97.6 cm. The WC cut offs did not differ between those with and 
without hypertension in both males and females. However, the values appeared 
slightly higher among those without raised blood pressure. 
Discussion 
The purpose of this study was to determine gender specific optimal cut off 
values of WC that best predict indicators of a cluster of metabolic risk criteria in a 
large, nationally representative sample of African American adults. The WC 
thresholds that best predict the cluster of metabolic risk factors in African American 
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males and females were found to be 95 cm and 98 cm, respectively. Compared to IDF 
(≥80 for females and ≥94 cm for males) and NCEP/ATP III (≥88 in females and ≥102 
cm in males) definitions of central obesity (2,29), the threshold suggested for males 
(95 cm) was similar to the IDF cut off value of 94 cm, but lower than the NCEP 
ATPIII currently used WC of 102 cm. Among females, in contrast to the IDF (80 cm) 
and NCEP III (88 cm), the cut off value was higher and equivalent to 98 cm. Females 
developed metabolic risk factors at higher WC in comparison to males. Overall, we 
observed that our cutoff values of WC for males yielded maximum sensitivity and 
specificity (Figure 4).   
The lower cut off value for WC in males compared to the 102 cm (8), which 
predicts the obesity BMI in Europeans, highlights the heterogeneity in values of WC 
and associated metabolic risk factors in different ethnic groups and populations.  
Indeed, other groups such as Asians who develop MetS at lower cut off values have 
revised their criteria (226) and new thresholds have been suggested.  In addition, 
lower WC values in African Americans (16), particularly among males, below the 
levels of WC estimated from BMI in European Americans have challenged the long 
held assumptions of a similar WC threshold across ethnic and racial groups in 
assessing MetS criteria (17). Thus, there is no support for choosing a WC threshold 
predicted from BMI cut-offs among African Americans. WC recommendations 
should be based on WC and its relationship to metabolic risk factors.  
Although sampling methods, measurements and indicator differences preclude 
direct comparison of our findings with previous studies, a recent study of Sumner et 
al (2008), to determine the WC in African Americans that best predict the insulin 
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resistance based on convenient sample of adults 20-50 years old, suggested a similar 
WC threshold of ≥ 98 cm in females (13).  An earlier study of Okosun et al (2000) 
using NHANES III to determine the WC associated with established BMI cut off 
values suggested  a WC of 97 cm for females and 101-103 cm in males (17). The 
same authors also assessed the ability of 102 cm and 88 cm in predicting MetS risk 
factors (15), and their findings confirm our current study, which found lower 
sensitivity at 102 cm for males (41-56%) for the different MetS components , and a 
very low specificity  for the 88 cm in females (31-37%). Zhu et al, (2005) estimated 
WC corresponding to the established overweight and obese values when one or more 
metabolic syndrome components were present.  The authors suggested 91 cm for 
females and 97 cm for males, however, the MetS criteria they used had different 
values than ones we used in this study. All the previous studies suggested a higher 
WC for females than the current 88 cm and the current study identified the optimal 
cut off values that are associated with both individual and the cluster of MetS risk 
factors. 
The major limitation of this study was the lack of availability of data for 2007-
08 to increase the sample size of the subsample for triglycerides and fasting blood 
glucose. This might have affected the lack of significant differences in WC thresholds 
by age categories (not reported) and for individuals with and without high blood 
pressure.  Secondly, this study is a cross-sectional design and gives limitd
information on the susceptibility to MetS risk factors.  A longitudinal study would be 
needed to determine the association between WC and incidence of the MetS criteria. 
Furthermore, this study did not assess the intra- abdominal distribution of adipose 
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tissue in relation to WC and metabolic risk factors. Further research would be need d 




In summary, we used the ROC curve analysis to determine appropriate WC 
cut off values for individuals with multiple metabolic risk factors among African 
Americans.  Findings showed that the WC thresholds, with relatively high sensitivity 
and specificity, are 95 cm for males and 98 cm for females, respectively.  The present 
findings suggest that those cutoffs be used for the early detection and management of 
MetS. Since this study was cross-sectional in nature, further investigation of long-
term morbidity/mortality data are needed to confirm the appropriate definition of 

















Table 1. Metabolic syndrome criteria based on NCEP-ATPIII and IDF 
consensus 
 
 NCEP ATP III a IDF  a 
Waist circumference 
  Men 
 
>102 cm WC 
 
Europids ≥ 94 cm* 
South Asians/Chinese ≥ 90 cm* 
Japanese ≥ 85 cm* 
 
Women >88 cm WC Europids ,South Asians/Chinese ≥ 80 cm* 





≥150 mg/dL (1.7 mmol/L) or treatment for this lipid abnormality  
 
≥100 mg/dL (5.6 mmol/L) or treatment of elevated glucose 




<40 mg/dL (1.03 mmol/L) or drug treatment for reduced HDL 
<50 mg/dL (1.29 mmol/L) or drug treatment for reduced HDL 
 
≥130/85 mm Hg or treatment of previously diagnosed hypertension 
Women 
Blood pressure 
NCEP-ATPIII: National Cholesterol Education Program-Adult Treatment Panel III; IDF: International Diabetes 
Federation; WC: waist circumference; OGTT: Oral Glucose Tolerance Test; HDL: High Density Lipoprotein 




























Table 2. Characteristics of the study population 
                  Men                                              Women 








LHDL- C (mg/dL) 
LTG (mg/dL) 
FBG (≥ 100 mg/dL) 
subjects with risk factors* 
      no risk 
      1 risk factor 
      2 risk factors 
      3 risk factors 
      4 risk factors 
  41.8 ±0.42 
  87.5 ±0.54 
177.1±0.15 
  27.8 ±0.16 
  95.7±0.39 
127±0.38 
  75±0.43 
  49.9±0.45 
100.5±2.44 





  55 
  28 
  20-85 
  38.9-156.4 
151.7-204.1 
  16.1 -47.4 
  62.4-144.7 
  90-217 
  35-116 
  48.9-50.8 
95.8-105.5 






  5% 
  42.9±0.43 
  82.5 ±0.57 
162.9±0.19 
  31.1 ±0.23 
  98.0 ±0.57 
 125±0.74 
  72± 0.41 
  56.5±0.47 
86.5 ±2.17 





  74 
  20 
  20-85 
  38.9-163.0 
149.9-184.7 
  17.4-57.6 
  60.4-145.0 
  79-266 
  40-112 
  55.6-57.4 
82.3-91.0 






  4% 
Mean ±SE or number of subjects and proportion of subjects (%) 
‡AGE t value -4.16 p = 0.001; weight t value 6.64 p=0.0001; Height t value = 59.26 p <0.0001; BMI -12.38 p < 
0.0001; WC -3.68 p < 0.0005; DBP t value  4.95 P =<.0001, TG t value = 4.06 p =0.000.  
BMI: Body mass index = Body weight (kg) / height (m)²;  WC, waist circumference;  SBP, systolic blood pressure;  
DBP, diastolic blood pressure; LHDL, log of   high density lipoprotein cholesterol; LTG, log of  triglycerides.  
























Table 3. Anthropometric profiles and medical examinations results by gender 
and 10 years age category, NHANES 1999-2006 
 
 Females (n= 1408) 
















Weight (kg)   78.7 ±  1.5   84.4 ±  1.5   84.1 ±  1.0   84.8 ±  1.3   84.3 ±  1.2   74.8 ±  1.3 
Height (cm) 163.1 ±  0.4 163.9 ±  0.5 163.4 ±  0.4 163.0 ±  0.5 161.9 ±  0.5 158.8 ±  0.5 
WC (cm)   92.6 ±  1.3   97.4 ±  1.4   99.1 ±  0.9 100.3 ±  0.9 102.7 ±  0.9   98.1 ±  1.1 
BMI ( kg/m²)   29.5 ±  0.5   31.3 ±  0.6   31.5 ±  0.5   31.8 ±  0.5   31.9 ±  0.4   29.6 ±  0.5 
SBP (mmHg) 111.6 ±  0.9 116.8 ±  1.1 125.4 ±  1.5 131.4 ±  1.3 141.1 ±  1.3 147.9 ±  2.2 
DBP (mmHg)   67.1 ±  0.7   72.4 ±  0.7   75.5 ±  0.9   76.1 ±  0.7   74.3 ±   0.8   67.15 ± 0.9 
TG (mg/dl)   86.6 ±  5.2   86.5 ±  4.5   96.3 ±  4.5 130.5 ±  12.8 120.1 ±   6.1 108.5 ±   5.4 
HDL(mg/dl)   54.9 ±  1.1   56.3 ±  1.1   58.7 ±  0.8   61.9 ±   1.1   60.1 ±   1.3   65.1 ±   1.8 
FBG (mg/dl)   89.7 ±  1.1   94.1 ±  1.8   97.0 ±  1.3 110.4 ±  5.4 110.6 ±  3.6 111.6 ±  4.2  















Weight (kg)    86.5 ±  1.2   89.4 ±  1.3   88.2 ±  1.0   87.5 ±   1.4   87.3 ±  1.4   79.0 ±   1.2 
Height (cm) 178.4 ±  0.4 177.4 ±  0.4 177.3 ±  0.3 176.8 ±   0.5 175.7 ±  0.5 171.8 ±   0.6 
WC (cm)   90.4 ±  0.9   95.6 ±  1.1   96.9 ±  0.8   98.5 ±   1.0 101.6 ±  1.2   98.6 ±   0. 9 
BMI ( kg/m²)   27.1  ±  0.4   28.3 ±  0.4   28.0 ±  0.3   27.9 ±   0.4   28.3 ±  0.4   26.7 ±   0.4 
SBP (mmHg) 120.1 ±   0.7 122.7 ±  0.8 127.2 ±  0.9 133.7 ±   1.4 135.0 ±  1.6 143.1 ±   2.1 
DBP (mmHg)   69.6  ±  0.9   74.3 ±  0.8   78.9 ±  0.8   80.1 ±   1.0   74.1 ±  0.9   71.4 ±   1.4 
TG (mg/dl)   97.5  ±  5.1 140.9 ± 13.8 131.8 ±  7.9 126.4 ±   0.1 122.4 ±  7.7 105.6 ±   6.6 
HDL(mg/dl)   51.0  ±  0.9   50.1 ±   0.9   51.2 ±  0.9   54.4 ±   1.2   52.9 ±  0.9   54.4 ±   1.4 
FBG (mg/dl)   93.4 ±   1.9   98.3 ±  1.4 101.5 ±  2.4 112.5 ±   3.7 127.5 ±  6.5 109.3 ±   4.9  
Values mean and standard errors WC: Waist circumference; BMI: Body mass index; SBP: systolic blood pressure, DBP: 




















Table 4.  Estimated waist circumference which predicts the cluster of metabolic 














≥  89 
≥  92 
≥ 94.7a 
 ≥ 95 
≥  98   
≥  102b 
≥  105 

































































≥  83 
≥  88b 
≥  93 
  ≥ 97.6a 
≥  98 
≥  103 
≥  105 
 
  0.22 
  0.29 
  0.32 
  0.33 
  0.32 
  0.30 
  0.29 
 
    0.744 
    0.624 
   0.526 
   0.476 
   0.481 
   0.504 









































WC = waist circumference. Jvalue = Youden Index. Minimum distance from the upper left corner of the point n 
the ROC curve. NPV: negative predictive values. PPV: positive predictive values. a author’s recommendations. b  































WC: waist circumference; BP: blood pressure; FBG: fasting blood glucose; HDL: High density lipoprotein; MetS: presence of ≥


















HDL ≤ 40 
mg/dL 
MetS 





































































































































































HDL ≤ 50 
mg/dL 
MetS 

















































































































































































AUC (95% CI) 0.65 (0.61-0.68)    0.71(0.67-0.75)     0.68 (0.63-0.72)      0.62 (0.57-0.67)    0.72 (0.68-0.76) 
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Table 6 .  Comparison between participants with and without raised blood 
pressure  NHANES 1999-2006 
  Men (558) Women(549) 
  Without 
HBP* 
With HBP Without HBP With HBP 
# observations 







± 70 yr 
Body mass index * 
Waist circumference * 








































 6 (2%) 
26 (9%) 







Mean ±SE or % of participants 
*Body weight (kg)/(m)²  ;  waist circumference (cm); HBP high blood pressure (mm Hg)  
**subjects with 2 or more of MetS risk factors: raised systolic BP and/or diastolic BP, high triglycerid s, reduced 
HDL-C and raised fasting plasma glucose 
 
 
Table 7.   Gender –specific WC cutoffs for detecting clustering of MetS risk 
factors including patients with and without raised HBP 
  Men Women 
  Without HBP With HBP Without HBP With HBP 
WC (cm) 


































WC: waist circumference (cm); HBP: high blood pressure; * Least distance from upper left to ROC curve 
















Figure 1. Prevalence of Metabolic Components in African Americans by 
Gender-NHANES 1999-2006 
 
HTG: high triglycerides; HFBG: high fasting blood glucose; LHDL: Low high density cholesterol;  
HBP: high blood pressure. 
 





- NHANES 1999-2006 
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Figure 3.  New Waist circumference cut off points for the detection of the cluster 
of high blood pressure, hyperglycemia, triglyceridemia and low high density 
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Figure 4. NCEP/ ATP III Waist circumference cut off points for the detection of 
the cluster of high blood pressure, hyperglycemia, triglyceridemia and low high 
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PAPER 2: APPROPRIATE BMI AND COMPARISON OF THE BMI THRESHOLD 
VALUES IN PREDICTING METABOLIC SYNDROME RISK FACTORS  
 
Abstract 
Existing BMI cut off values have been debated as to whether they are appropriate 
across different population groups as they do not account for body fat distribution and 
their association with health outcomes remains unclear in certain groups. 
 The purpose of the study was to determine appropriate African American (AA) body 
mass index (BMI) cut points to account for differences in obesity related metabolic 
risk factors. It also studies the gender differences in the relationship of BMI to body 
composition. 
The study comprised of 4415 of adults aged 20 and older and 49% were males. Males 
were younger than females (41.7 years vs. 43.9 years, respectively) and their average 
age increased correspondingly with BMI categories, ranging from 36.7 – 44.6 years.
The opposite was observed in females, where the age slightly decreased with 
increasing BMI values.  From receiver operating characteristics analysis (ROC), the 
optimal cut-off points for BMI were found to correspond to 28 kg/m² in males and 32 
kg/m² in females. The BMI cut points predicted from the presence of MetS risk 
factors are lower in males and higher for females than the currently defined cut off 
values of 30 kg/m². WC corresponding to the newly estimated values of BMI in males 
and females were tested using simple linear regression and ROC and were 96 cm and 
99 cm, respectively. The findings differed from the current NCEP-ATPIII WC values 
in males (102 cm) and in females (88 cm) predicted from the BMI.  
81 
 
In summary, the current study results show the need to consider ethnic background in 
defining the BMI cut–off values that predict the presence of health risk factors. 




Body Mass Index (BMI) is used to assess overall heaviness (227). There are 
no established cut-off points for fat mass or percentage body fat (%BF) that transla e 
into cut-offs for BMI, which relates weight/(kg) to height (m²). The World Health 
Organization (WHO) defines overweight as a BMI 25-29.9 kg/m² and obesity as BMI 
≥ 30 kg/m².  Such recommendations were promulgated primarily for European 
populations to correspond to risk thresholds for a wide range of chronic diseases and 
mortality (161). The epidemiological data show increased mortality at BMI ≥ 25 
kg/m² (167-169, 172). This increase, however, appears modest until a BMI of 30 
kg/m² is attained.  Individuals with a BMI of ≥ 30 kg/m² have a mortality rate from all 
causes, and cardiovascular disease (CVD) in particular, 50-100 % above those whose 
BMI fall in the normal range of BMI 20-25 kg/m² (167,171).  
Among African Americans (AA), available studies suggest that adiposity may 
be a less important predictor of mortality than in European Americans (EA), 
especially among females (228). In individuals who never smoked and without 
history of disease, the association between a high BMI and elevated risk of death was 
observed to be more moderate among AA males and females. A small increase in risk 
of death was found only at BMI 35.0 or higher (228) among AA females. Two large 
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U.S. surveys – the National Health and Nutrition Examination Survey (NHANES) 
and the National Health Interview Survey (NHIS) showed that the BMI-related to 
increased mortality begins at a 1 to 3 kg/m² higher BMI level among African 
Americans than among European Americans. The BMI associated with minimum 
mortality was 26.8 kg/m² for AA females and 27.1 kg/m² for AA males compared to 
24.3 kg/m² and 24.8 kg/m² in EA females and males, respectively (229). 
The use of WHO BMI cut off values for overweight (25 kg/m²) and obesity 
(30 kg/m²) has limitations (10, 22). The BMI measurement is disputed because its 
correlation with body fatness is inconsistent across populations (24-27). In addition, 
there has been ongoing debate as to whether these criteria (for obesity and 
overweight) are appropriate for non-European populations as they do not account for 
differences in body fat distribution and the relation of body size and composition with 
health outcomes (25). BMI does not separate fat mass from fat free mass (muscle and 
skeletal masses). Studies have shown that individuals with identical BMI values may 
have considerably different percentage fat levels, particularly if they vary in ge, 
gender and ethnicity. Compared to other ethnic groups, African Americans have been 
reported to have higher total bone density and muscle mass content (24) across the 
lifespan. Using dual energy X-ray absorptiometry (DEXA), the percentag  of body 
fat (BF) estimated at a given BMI was lower in African Americans than in European 
Americans. Thus, the relationship between percentage fat and BMI is probably 
different among African Americans, given the increased skeletal muscle mass and 
lower percentage BF.  It is not surprising that a change in this relationship may 
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suggest that African American females in particular may be at decreas d metabolic 
risk compared with Europeans at similar BMI levels (12).  
Since population groups may differ in the level of risk associated with a particul  
BMI,  research is needed to determine appropriate African American BMI cut points 
to account for differences in (i) susceptibility to obesity-related metabolic risk factors, 
(ii) the relation of BMI to body fatness and fat free mass, and (iii) fat distribution. 
This study focuses on appropriateness of BMI cut offs in adult African American 
males and females. The optimum BMI levels based on their specific Metabolic 
Syndrome (MetS) risk profiles will be determined. The results will contribute to our 
understanding of ethnic differences in metabolic syndrome and its implication for 
chronic disease disparities. 
 
Research Design and Methods 
Data source and sample size  
 The study analyzed data from the National Health and Nutrition Examination 
Survey (NHANES) data collected between 1999 and 2006 on African Americans 
(230). NHANES survey comprises a series of cross-sectional studies, which uses a 
complex, multistage probability, stratified and cluster sampling design survey. It was 
designed to monitor and evaluate the nutritional and health status of a representative 
sample of the non-institutionalized U.S. population. The assessment is based on 
health-related household questionnaires, laboratory tests and physiological 
measurements. Detailed information on NHANES data collection procedures are 
available elsewhere (231). Individuals aged ≥ 60 years of age, low income European 
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Americans, Mexican Americans and African Americans were oversampled to ensure 
accurate estimates in those population groups.   
This NHANES sample comprised of 4415 AA adults ≥ 20 years. Of the total 
number, 3842 subjects were interviewed and completed the clinical examination in a 
mobile examination center (MEC).  After the exclusion of pregnant and lactating 
women, those using insulin and others who reported having cancer, 3124 remained in 
the analysis.  
The final sample consisted of 1445 subjects, with complete data on all the 
MetS criteria, were used to determine the BMI threshold values to predict MetS risk 
factors. 
Socio demographics and economic status 
 Socio-economic variables such as age, gender, education, marital status and 
poverty income ratio (PIR) were included in the analysis. Education level was 
categorized into three groups: < 8 yr, 8-12 yr, and > 12 yr of education. Poverty 
income ratio from NHANES was computed as a ratio of income to the family’s 
pertinent poverty threshold established by the US Census Bureau in a given year 
calendar (232). The following NHANES definitions were used, a PIR ≥ 1.0 is 
indicative of income above the poverty level while <1.0 is below the official poverty 
threshold. The PIR categories were defined as <1.85 indicating low, ≥ 1.85-3.5 as 
medium, and >3.5 as high socioeconomic status. Age was grouped into 6 categories: 





Dietary and lifestyle factors  
Smokers were designated as current, past, and never smokers.  Individuals 
who had smoked ≥ 100 cigarettes during their lifetimes and who reported not 
currently smoking were considered as past smokers. Drinking was classified into 
three groups: Heavy, moderate, and non-drinkers.  Heavy drinkers were individuals 
who ever drank ≥ 5 alcoholic beverages per day or drank daily at least one beer, wine, 
or hard liquor for the past month. Dietary habits were coded on the basis of energy 
intake from fat (< 25%; 25-35%, > 35%) and carbohydrate (<45%; 45-65%, & > 
65%). Physical activity was based on three levels of average level of physical activity 
per day as defined by NHANES (230). Sitting during the day with not much walking 
was defined as sedentary.  Standing or walking a lot during the day was considered as 
moderate.  The most active participants were those who climbed stairs or hillsften, 
did heavy work or carried loads (233). 
Measures: Biochemical and Definition of metabolic risk factors 
 Biochemical samples were collected during the MEC examination. Fasting 
blood glucose was determined by the glucose oxidase method quantified using 
hexokinase enzyme (234). Serum triglyceride was measured enzymatically with the 
hydrolysis of glycerol. High – density lipoprotein was measured after the 
precipitation of other lipoproteins with heparin-manganese chloride mixture or with 
direct method. Biochemical analyses were carried out using Hitachi 706 (serviced by 
Roche Diagnostics, Indianapolis, IN) (235).  
For this study, participants were considered to have a high risk for MetS if 
they had at least any two of the following 4 components: 1) dyslipidemia – high 
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triglycerides ≥ 150 mg/dL and low HDL 40 mg/dL for males and < 50 mg/dL for 
females; 2) hyperglycemia ≥ 100 mg/dL or oral treatment for diabetes; 3) 
hypertension – systolic blood pressure (SBP) and /or diastolic blood pressure (DBP) 
of ≥130 mmHg and ≥ 85 mmHg, respectively, or they were on treatment for any 
abnormal indicator.  
NHANES Physical & anthropometrics measure  
The blood pressure was measured using a standard mercury 
sphygmomanometer to the nearest two mmHg on the right arm with the subject 
seated and having rested for at least 10 minutes. The average of the last two readings 
was taken as the subject’s blood pressure. When there were only two readings, the 
last reading was considered as the individual’s blood pressure.  The waist 
circumference (WC) was measured using a steel tape at the top of the iliac area. 
Electronic scale was used to measure the body weight in kilograms, while the height 
was estimated using a calibrated stadiometer. Body mass index [weight (kg)/height 
(m²)] was calculated for every subject on the basis of collected weight and height 
(236), and was categorized into 6 groups (<23, 23-27.49, 27.5 – 29.99, ≥ 30 and ≥ 40) 
(237). Post-menopausal status was described as having complete cessation of menses 
for ≥ 12 months. 
During data collection in NHANES /MEC, a whole body scan was administered for 
eligible subjects during the 3-year cycles of 1999 - 2004 using Hologic QDR-4500A 
fan-beam densitometer (Hologic Inc., Bedford, MA).  Pregnant females, individuals 
who reported nuclear medicine studies, use of barium contrast in the past 7 days, a 
weight > 300 lbs or height > 6 ft 5 were excluded from the DXA tests. The test 
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provided lean and bone tissue measurements for the total body.  Data on total mass 
(g), fat mass (g), lean mass (g), bone mineral content (g), bone area (cm²) and bone 
mineral density (g/cm²) were recorded. Percentage body fat (BF %) was calculated as 
total body fat mass over total mass X 100, and is a direct measure of an individual’s 
relative body fat.  Using sequential regression imputation methods (IVEware 
software), multiple imputation of the DXA data were made and five complete records 
were created for each participant. The imputation was to prevent bias that could result 
from the nonrandom missing data and ensure a more accurate standard error 
estimation. Pregnant Women and participants with amputations other than fingers or 
toes were excluded during the process. Detailed description of the multiple 
imputations can be found in the NHANES 1999-2004 technical documentation (238).   
Statistical Analysis 
Statistical analysis was carried out using SAS statistical package (version 9.2; 
SAS Institute Inc, Cary, NC) and STATA statistical software (Version 10.1 for 
Windows; Stata Corporation, College Station, TX) with adjustments for the complex 
sample design unless specified otherwise. The survey design variables include a 8 
year estimated sampling weight, the primary sampling units (PSU), and the strata. 
First, the distribution of body composition (%BF, TBF, FFM), anthropometrics and 
biochemical variables by sex was examined and logarithmic transformations were 
performed to correct departures from normality on some of the body composition 
measures.  A chi-square test was used to examine the differences in prevalence of 
MetS criteria by gender and BMI categories (<23, 23-25, 25-27.49, 27.5-29.99, ≥30 
and ≥ 40 kg/m²) as defined by WHO.  Based on the Rao-Scott Chi-Square test with 
88 
 
adjusted F statistics, the test of independence was considered statistically significant 
at p value < 0.05.   
Next, Receiver Operating Characteristic (ROC) analysis (215) was carried out 
separately for males and females to determine BMI values related to the presence of 
individual or ≥ 2 MetS risk factors. The components of MetS risk factors were used 
as outcomes. The best BMI thresholds and their corresponding sensitivity and 
specificity were defined based on the minimum distance from the upper left cornerof 
the ROC curve and the Youden’s index values. Area under the ROC Curve (AUC) 
was used as a measure of the overall accuracy of performance of the ROC test in 
predicting BMI cut off values for MetS criteria. The AUCs values of ≥ 0.7 - <0.8; 
≥0.8 - <0.9; and ≥ 0.9 correspond to the acceptable, excellent and outstanding 
classification (216,239). Then, using simple regression and ROC analysis, the WC 
values corresponding to the newly estimated and existent BMIs thresholds in males 
and females were determined. 
 Logistic regression was used to assess the association between increased risk 
of metabolic syndrome and BMI while adjusting for selected lifestyle and 
demographics variables. Two dummy variables were used to code low and high BMI. 
The BMI values estimated by this study as optimal BMI in predicting MetS risk 
corresponded to 28 kg/m² and 32 kg/m² for males and females, respectively. The low 
BMI (< 28 and < 32 kg/m²) served as the reference to facilitate the test of nonlinear 
relationship between BMI and MetS criteria while adjusting for covariates. 
Comparisons were made between the odds ratios and 95% CI for specified low and 
high BMI ≥ kg/m² while adjusting for age, education, smoking, alcohol intake, 
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dietary and physical activity. A value of p < 0.05 indicated statistical significa ce. 
The logistic regression models were modeled separately for males and females. Two 
way interaction terms were examined in each gender specific model and were 
dropped when there were not statistically significant.  
Weighted correlation between BMI/WC and blood glucose, blood pressure, and lipid 
profiles was run by gender while adjusting for age. Furthermore, Pearson’s 
correlation analysis was used to assess the degree of linear association between WC 
and BMI, as well as body composition (fat and fat free mass). Subsequently, multiple 
linear regression analysis was performed to evaluate the relation between BMI a d 
body fat and fat free mass measures. This was done to assess their contribution to the 
variation in BMI among African Americans. All regressions were done separately for 
males and females while controlling for age. Statistical tests were conducted at the p-
value less than 0.05 significance level. For the analysis of the 5 multiple imputation 
NHANES data, the “mim” estimation procedure was carried out to take imputation 




A total of 4415 participants met study criteria and 49.1% were Males. 
Demographic characteristics are summarized in Table 8 by gender and body mass 
index categories. Males were younger than females (41.7 years vs. 43.9 years, 
respectively) and their average age increased correspondingly with BMI categories, 
ranging from 36.7 – 44.6 years. The opposite was observed in females, with the 
average age slightly decreasing with an increase in BMI values. Between 43.7 –
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72.5% of Males had up to high school education level. Males with a BMI of ≥ 40 
kg/m² showed the lowest percentage of individuals with greater than high school 
(27.5%). For females, the education attainment of high school and > than high school 
was on average 47%. In the case of females who completed more than high school, 
the education rate was similar across BMI categories with variation at BMI values of 
23-25 kg/m² (53%) and 27.5-29.9 kg/m² (38%). A statistically significant association 
(p value <0.05) between PIR and BMI categories was observed among males. The 
lowest PIR (< 1.85) was recorded in 49-53% males with lower BMI categories f 25 
kg/m² and below. On average, 37.5% of males with a BMI > 25 kg/m² had a PIR > 
3.5, while those with a PIR < 1.85 were 32%.  In general, among females, a greater 
percentage (49%) had a lower PIR < 1.85 compared to Males (39%). A higher 
percentage (32.3-38.8%) of females with a BMI below 25 kg/m² had a PIR > 3.5 
compared to those (21-25%) with BMI 25 kg/m² and above.  
 
Prevalence of MetS criteria across BMI categories 
Variations in prevalence of MetS risk factors by gender and across BMI 
categories are shown in Figure 5 and 6. There was a statistically significant 
association in MetS criteria with the BMI categories in males and females. In males, 
high fasting blood glucose (HFBG), high blood pressure and low HDL showed an 
increase percentage with high BMI categories.  On the other hand, high triglycerides 
showed a similar trend but a decrease after BMI of 30 kg/m². High blood pressure had 
the highest prevalence rate in males and females. In females, the highest rate of MetS 
criteria were high blood pressure, low HDL and high fasting blood glucose (HFBG). 
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Among the MetS criteria, triglycerides showed the lowest prevalence rate with a 
proportionate decrease in both females and males after the BMI of ≥30kg/m². 
 
BMI cut-offs values based on the presence of MetS risk factors 
Table 9 & 10 summarize gender specific BMI thresholds related to the 
presence of individual or two or more MetS risk factors.  Among males, the BMI 
thresholds for individual MetS components range between 27- 29 kg/m². The cut off 
value of having a cluster of the risk factors showed optimal combination of sensitivity 
and specificity at close to 28 kg/m².  Compared to males, the MetS criteria in females 
were observed at higher ranges of BMI. As illustrated in the Table 9, high blood 
pressure was noted at BMI between 29-30 kg/m², high fasting blood sugar was at 31-
32 kg/m², and high triglycerides and low HDL at 32-33 kg/m². Consequently, in 
females, the findings based on sensitivity and specificity suggest a BMI of  32 kg/ m²
as the most appropriate  cut off value to identify the cluster of metabolic syndrome. 
Sensitivities, specificities and Areas under the ROC curve to identify BMI 
thresholds are shown in Figure 7. It is noted that a BMI of ~ 28 kg/m² was the most 
sensitive and specific to identify male participants with MetS conditions, whereas in 
females the corresponding value was higher and equal to ~ 32 kg/m².  Using ROC 
curve analysis, the newly estimated BMI cut off values correspond to the waist 
circumference of 96.3 cm (sens=0.87, spec=0.86) for males and 99.2 cm (sens=0.86, 
spec=0.89) for females. The estimated WC for females was also higher than males 
under this analysis. Based on a simple regression analysis model, the WC values 
based on the following equations:  WC = 25.105+2.545*BMI for males and WC = 
92 
 
37.944+1.938*BMI for females were similar (96.3 cm for males and 99.9 cm for 
females) to ROC values.  
Adjusted association between MetS criteria and BMI 
Logistic regression was used to assess the association between BMI and the 
likelihood of having MetS among African Americans 20 years and older after 
adjusting lifestyle and demographic covariates. The independent covariates which 
were examined for incorporation into the final model included age, education, 
smoking, alcohol consumption, dietary and physical activity.  It appears that among 
males, each of the following predictors in the multivariate models: MetS criteria, age 
categories, fat intake and smoking status had significant or marginally significant 
relationship with the probability of having a high BMI (28 kg/m²) after adjusting for 
the relationships of the other predictors. In females, only age categories and MetS 
components showed a statistically significant association with having a BMI of 
≥32kg/m². 
Focusing on the primary predictor variables of interest, (MetS components), 
the results show that in males the odds of having a BMI 28 kg/m² and above are 
multiplied by 2.4 when a person has high blood pressure, 1.9 with high triglycerides, 
1.2 for high fasting blood glucose, and 1.3 for low HDL after adjusting for the 
selected demographics and dietary covariates.  Among females, relative to 
respondents with normal blood pressure, those with higher blood pressure had 
significantly higher (150% higher) odds of having a BMI ≥ 32 kg/m² when adjusting 
for age categories. It was also noted that relative to participants with normal 
triglycerides levels, having high triglycerides was associated with a 2.1 times odds of 
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high BMI.  Further,  individuals with high fasting blood glucose had significantly 
higher odds of (3.6) of being in the category of ≥ 32 kg/m², while low HDL 
cholesterol  had significantly higher odds (2.3) of  BMI ≥ 32 kg/m² in comparison to 
participants with normal HDL cholesterol.   
Correlation and multiple regression 
In males, there was a high correlation between BMI and % body fat mass (.827) and 
fat free mass (FFM) excluding bone content (.865).  In females, the same high 
correlations were observed as shown in Table 11.  Under the MetS criteria and BMI 
correlation, the high relationship was observed with WC for males and females. Other 
MetS criteria showed positive weak correlation with BMI. Only the low HDL 
cholesterol had a negative relationship with BMI. 
Multiple linear regression analysis was used to investigate the possible 
influence of  lean fat mass, bone content mass, gender and age on the relation 
between BMI and body fat. BMI was used as the dependent variable.  Data for males 
and females were analyzed separately (Table 12). P- values were considered 
significant at p < 0.05. Among males, the age and interaction terms (not shown) were 
not statistically significant and were excluded from the models. The body fat mass 
explained 88 percent of the variance in BMI.  The combination of body fat mass and 
lean body mass increased the explained percent of variance to 92 percent. No 
significant additional variance was explained by the addition of bone mass content 
and age. For females, the largest percent of BMI variance was explained by bo y fat 
mass (91.8%).  The incorporation of lean body mass, bone mass and age marginally 
increased the R2 value to 93 percent. 
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Discussion and Conclusion 
 The existing WHO and NIH cut off values for BMI of 25 and 30 kg/m² were 
established to delineate overweight and obesity based on observed trends in the 
relationship between the BMI and morbidity and mortality rates (161) in European 
Americans. The focus of the current study was to assess the unique relationship 
between BMI and metabolic health risk factors for African Americans, and the health 
risks that accompany excess adiposity. The optimal cut-off points for BMI were 
found to correspond to 28 kg/m² in males and 32 kg/m² in females. These BMI cut-
offs which were predicted from the presence of MetS risk factors, are lower in males 
and higher for females than the currently suggested cut off values of 30 kg/m². This 
study confirms that African American females experience health issues at high BMI 
and this is in agreement with a previous study, which observed a small increase in 
risk of death at BMI 35kg/m² or higher among AA females (228). Thus the practice 
of using a single BMI standard by gender and race is not supported.   
Using simple linear regression and ROC analysis, WC corresponding to the 
newly estimated values of BMI (28 and 32 kg/m²) in males and females were 96 cm 
and 99 cm, respectively. These findings differ from the current NCEP-ATPIII WC 
values of ≥ 102 cm in males and ≥ 88 cm in females predicted from the BMI of 30 
kg/m² (7,8). The lower threshold for WC in African American males compared to 
European Americans underlines the heterogeneity in WC values associated with 
metabolic risk factors in different population groups. Using the NCEP-ATPIII 
definition of central obesity has contributed to the underestimation of the prevalence 
of MetS among African American males. Further research is needed to compare the 
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intra-abdominal adipose tissue in relation with to WC and metabolic risk factors in 
this population.  
The relationships between our new BMI calculated cut offs ( > 28 and 32 
kg/m²) and the presence of MetS risk factors confirmed a high prevalence of high 
blood pressure among African Americans males and females (241). At BMI greater 
than 28 kg and 32 kg/m², the odds of having a high blood pressure was 140-150% 
compared to participants with normal blood pressure. Although the risk of having 
abnormal triglycerides has been estimated to be lower in African Americans 
compared to European Americans (242, 243), the odds of having high triglycerides 
levels were ~2 times greater among participants with higher BMI for both males and 
females, after adjusting for lifestyle and socio-economic covariates. This finding 
however is not in agreement with previous studies which indicate that 
hypertriglyceridemia (TG ≥ 150 mg/dL) tends to be lower at all levels of BMI in 
African Americans (243).  However, the inclusion of covariates (demographics and 
lifestyle) in our study might explain this discrepancy.  Some investigators have 
suggested the use of ≥ 130 mg/dL as the cut off value for TG (244) but further studies 
are still needed to determine the appropriate TG threshold for African Americans. 
Compared to males, the odds of high blood pressure and low HDL were lower in 
females.  There was a 20% and a 30% increase in odds for high fasting blood glucose 
and low HDL respectively among males with a BMI > 28 kg/m² compared to those 
with lower BMI. The odds were highest for elevated blood glucose and low HDL 
among African American females (3.6 and 2.3 times) > 32kg/m². Previous studies 
have shown a similar significant association between BMI and elevated glucose 
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levels among African Americans (245). Community based screening for diabetes may 
enhance the diagnosis of prediabetic and diabetic status among African Americans to 
insure early intervention. 
BMI is considered a proxy for fatness. Of interest to us, this study was also to 
examine the gender differences in the relationship between BMI and body 
composition. Multiple regression was run with BMI as the dependent variable while 
adjusting for age. The present study confirmed a high correlation between BMI and 
body fat and lean mass. The body fat mass explained a higher percent of the variation 
in females BMI value (91.8) compared to males (88%). This relationship was 
significantly influenced by age in females. The addition of lean mass increased the 
variance to 93%, thereby explaining a small increase but significant variance of BMI 
in males. These findings confirm a higher fat mass among African American females 
and are in agreement with previous reports (246). Further studies would be needed to 
determine BMI that best classifies individuals according to body fat, while taking into 
consideration the variation in lean body mass.  
This study was based on a cross-sectional data set, and further studies are 
needed to confirm our findings in longitudinally monitored subjects. In summary, the 
current study results show the need to consider ethnic background in defining the 
BMI cut–off values that predict the presence of health risk factors. Furthermor , this 
study confirmed a lower WC in males compared to females. Although body fat mass 
is a useful measure in predicting BMI status, lean body mass significantly co ributed 






Table 8.  Participant characteristics and body composition by body mass index 
categories among African American adults. NHANES : 1999-2006 
 
 BMI (kg/m²)  
 Overall < 23 23-25 25-27.49 27.5-29.99 ≥ 30 ≥ 40 
Males (n=) 
Age ( years) 
 
Education(%) 
< high school 
= high school 
>high school 
*PIR 
  PIR <1.85 
  PIR 1.85-3.5 





< high school 








41.7 ±  0.65 
 
   
  5.8  ± 1.29 
49.5 ±  2.98 
44.6 ±  2.76 
 
39.7 ±  2.56 
27.9 ±  2.18 
32.4 ±  2.61 
 
2246 
43.9 ±  0.77 
 
   5.6 ±  0.92  
47.1  ±  2.63 
47.3  ±  2.59 
 
49.2  ±  2.78 
 24.7 ±  1.66 





  3.3  ±  1.56 
59.7 ±   5.62 
36.9 ±   5.29 
 
49.4 ±   4.82 
21.9 ±   4.73 
28.7 ±   5.29 
 
282 
44.7 ±  2.13 
 
  5.13 ± 2.12 
45.6  ±  7.28 
49.2  ±  7.58 
 
44.7  ±  7.87 
22.9  ±  5.49 




40.1 ±  1.99 
 
   
  7.3 ±  2.98 
51.7 ±  6.82 
40.9 ±  7.00 
 
52.9 ±  7.26 
28.9 ±  6.31 
18. 2 ± 5.69 
 
220 
48.3 ±  1.44 
 
   9.6 ±  3.47 
37.2 ±  6.95 
53.1 ±  6.83 
 
30.7 ±  7.70 
30.5 ±  6.59 




41.6 ± 1.91 
 
   
  5.8  ±  2.18 
37.9  ±  7.07 
56.2  ±  6.96 
 
27.9  ±  4.57 
35.3  ±  5.52 
36.8  ±  5.09 
 
275 
41.7  ±  3.00 
 
   7.7 ±  3.34 
43.5 ±   6.55 
48.8 ±   6.58 
 
59.9 ±   4.90 
18.1 ±   6.21 




43.2 ±  2.50 
 
   
  4.9  ±  2.39 
49.7  ±  5.76 
45.5  ±  5.69 
 
39.5  ±  6.53 
20.8  ±  5.61 
39.6  ±  6.88 
 
338 
43.9  ±  1.30 
 
  5.0  ±  2.64 
56.9  ±  6.91 
38.1  ±  6.95 
 
43.7  ±  7.65 
30.4  ±  5.42 




44.6  ± 1.32 
 
   
  6.9  ±  2.46 
43.7  ±  6.35 
49.3  ±  6.43 
 
30.4  ±  6.12 
31.5  ±  4.96 
38.0  ±  5.86 
 
856 
40.9  ±  1.85 
 
   5.2 ±  1.79 
47.8  ±  4.01 
46.9  ±  3.91 
 
49.3  ±  3.36 
28.0  ±  3.23 




43.2 ±  2.22 
 
 
11.2 ±    6.46 
61.3 ±  12.68 
27.5 ±  11.11 
 
33.3 ±  10.17 
31.1 ±  10.92 
35.6 ±  11.18 
 
275 
40.2  ±  1.28 
 
  2.9  ± 1.84 
46.3 ±  5.53 
50.8 ±  5.36 
 
60.4 ±  7.98 
14.1 ±  4.47 
25.2 ±  6.50 
 
 
Values are mean ± standard error and percentages. PIR = poverty index ratio 
SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglycerides. 


























HBP = high blood pressure; LHDL = low high density l poprotein; HTG= high triglycerides; HFBG = high fasting 
blood glucose.  
 
Figure 6.  Prevalence (%) of MetS criteria by BMI categories in Women 
  
 
HBP = high blood pressure; LHDL = low high density l poprotein; HTG= high triglycerides; HFBG = high fasting 
blood glucose.  
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Table 9. Sensitivity and specificity of BMI cut-offs for metabolic syndrome 
criteria in females – NHANES 1999-2006 
BMI: body mass index; BP: blood pressure; FBG: fasting blood glucose; HDL: High density lipoprotein; MetS: 
presence of  ≥ 2 criteria (BP, FBG, low HDL, high triglycerides); Sens: sensitivity; Spec: specificity. 
 
Table 10. Sensitivity and specificity of BMI cut-offs for metabolic syndrome 
criteria in males – NHANES 1999-2006 
 
BMI: body mass index; BP: blood pressure; FBG: fasting blood glucose; HDL: High density lipoprotein; MetS: 
presence of  ≥ 2 criteria (BP, FBG, low HDL, high triglycerides); Sens: sensitivity; Spec: specificity. 
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MetS 
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1-Specificity
BMI ROC Curves by Gender
Figure 7.  Receiver operating characteristics curves of the estimated cutoff values for 
BMI that predict ≥ 2 metabolic risk factors in males and females; NHANES 1999-2006 
           Sens = sensitivity; Spec: specificity; AUC: Area under the curve; BMI: Body mass index 
             ROC – Receiver Operating Characteristics. 
 
Table 11.  Pearson correlation coefficients between BMI and body composition 
for males and females measurements adjusted by age* 
 
Body measures   BMI (kg/cm²)  
MALES      
WOMEN 
       MetS 
criteria         
 
BMI (kg/cm²)  
                 
MALES     
WOMEN 
 






































lnFM= log of fat mass; BMC = bone mineral content; BMD= bone mineral density; FFM=fat free mass excluding 
bone mineral content; WC = waist circumference, BP = blood pressure, HDL = high cholesterol lipoprotein. *All 
coefficients are significantly greater than zero. 
 
Sens = 67 
  Spec = 67 
AUC = 0.70 
BMI 27.77 kg/m² 
Sens = 62 
  Spec = 65 
AUC = 0.68 (0.64-0.73) 
BMI 31.87 kg/m² 
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Table 12.  Multiple regression analysis of BMI versus body fat mass, body fat 






Coefficient ± SE Coefficient ± SE 
Intercept  9.457 ± 0.692 12.434 ± 0.814 
Body fat mass (kg)  3.654 ± 0.149*  4.562 ± 0.142* 
Lean body mass (kg)  2.278 ± 0.163* 2.223 ± 0.222* 
Bone mass content (kg) -1.503 ± 0.304*            -2.928 ± 0.407* 
Age  0.002 ± 0.006  -0.020 ± 0.005* 
R2   0.92 0.93 
























PAPER 3. THE PREVALENCE OF METABOLIC SYNDROME AS INFLUENCED BY 
MEASURES OF OBESITY & CORRELATES OF THE SYNDROME AMONG 
AFRICAN AMERICANS. 
Abstract 
Background: African Americans have a lower prevalence of metabolic syndrome 
(MetS) partly attributable to the use of metabolic criteria that may not be ethnic-
specific. Currently used cut offs values for waist circumference might not be 
appropriate for this group. Our objective was to estimate MetS prevalence usig 
previously developed WC cut-offs and our estimated appropriate WC  in a 
representative sample of adult African Americans. Additionally, the correlates of the 
syndrome were examined.  
Methods: A total of 4044 subjects ≥ 20 years of age were analyzed, of whom a 
subsample of 1445 had complete information on metabolic syndrome. Data were 
derived from the 1999-2006 National Health and Nutrition Examination Survey. 
Results: Using the National Cholesterol Education Program thresholds of ≥ 102 cm 
for men and ≥ 88 cm for women, the age- adjusted prevalence of metabolic syndrome 
was 25.8% among men and 35.9% among women.  Using the newly estimated waist 
circumference values of  ≥ 95 cm in men and ≥ 98 cm, an increase in age-adjusted 
prevalence of metabolic syndrome was observed as (30.9%) in men while it 
decreased to 30.3% for women. The estimated prevalence using the International 
Diabetes Federation  cut offs of ≥ 94 cm for men and ≥ 80 cm for women was  31.1% 
and 38.3%,  respectively. The latter prevalence was high in women. This was related 
to the low cut off value of 80 cm, which is too low for African American adult 
women. Our results also showed that individuals with MetS are impacted by 
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numerous physiological and biochemical abnormalities, as well as lifestyle choices 
which negatively affect their health status. 
Conclusion: The prevalence of metabolic syndrome is underestimated among African 
American Adults men. The continued increase in obesity and MetS syndrome is of 
health concern.   
 
Introduction 
The concept of metabolic syndrome (MetS) was introduced to characterize a 
simultaneous occurrence of several cardiovascular risk factors observed in the same 
subject. The clustering results in markedly high risk of diabetes and heart disease 
(65,247). In 2001, the National Cholesterol Education Program Expert Panel released 
the Third Report on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (NCEP/ATPIII), which provided a working definition of the metabolic 
syndrome (2,32).  In 2009, five key organizations reconciled various MetS definitions 
(29).  The condition is diagnosed when any 3 of the 5 metabolic risk factors are 
present. The risk factors consist of elevated triglycerides ≥ 150 mg/dL; glucose ≥ 100 
mg/dL; systolic blood pressure  ≥ 130 and/ or diastolic blood pressure  ≥ 85 mm Hg; 
reduced high density lipoprotein (men < 40 mg/dL; women <50 mg/dL); a waist 
circumference of  ≥ 102 cm for men and  ≥ 88 cm for women (29). The MetS 
definition also includes being treated for dyslipidemia, systemic hypertension and 
hyperglycemia, excluding use of insulin.  
Although the NCEP & IDF definition (30,57) are the most widely used as they 
provide a relatively simple approach and easily measurable risk factors to diagnose 
MetS, ongoing research has identified other risk factors associated with the 
104 
 
syndrome. MetS is a proinflammatory condition (2) characterized by high levels of 
micro-inflammation factors such as C - reactive protein (2,248,249), which is 
associated with a more deteriorated metabolic risk profile (250). MetS is also linked 
to a prothrombotic state with increased levels of fibrinogen concentration (251,252). 
Experimental studies have reported elevated alkaline phosphatase (ALP) with MetS 
and ALP might promote vascular calcification (253). Moreover, MetS is often 
associated with hyperuricemia (254, 255). As early as 1923, Kylin recognized that 
hyperuricemia, hypertension, and hyperglycemia tended to occur together (256). 
Other risk factors such as microalbuminuria, associated with insulin resistance and 
central obesity, is also included as an integral component of the MetS by some 
experts (58,203).  Nonalcoholic fatty liver has also recently been recognized as a 
hepatic manifestation of MetS and obesity (257-260) with elevated liver enzymes. 
These consist of gamma-glutamyl transferase (GGT) and alanine aminotransferase 
(ALT) (261-264).  
 The use of the NCEP/ATPIII criteria to estimate the prevalence of MetS 
shows it to be a growing problem in the USA. Approximately one-quarter of North 
Americans (72) are affected by MetS. However, current NCEP criteria have been met 
with debate in their ability to estimate the prevalence of MetS in different th ic 
groups (265,266). For example, in African Americans (AA) who are more prone to 
high blood pressure, type 2 diabetes (267), and high coronary heart disease mortality 
(268), a low MetS prevalence is reported. This prevalence is lower in AA men 
(25.5%) when compared to European Americans (EA) men (38.4%) (32). On the 
other hand, for women, the MetS prevalence is higher (38.2%) than among EA 
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women (31.3%). Given that the MetS criteria definition and prevalence for various 
population remains controversial (165), a review of the limitations of existing MetS 
definitions is needed. This study estimated the prevalence of MetS in AA based on 
WC cutoffs the authors estimated to be more appropriate to the AA group and 
assessed differential characteristics between Mets and non-MetS groups for selected 
variables. Understanding better the prevalence and correlates of MetS would 
significantly affect approaches to preventing diabetes and cardiovascular diseases 




Survey design and study sample 
We analyzed the National Health and Nutrition Examination Survey data 
collected between 1999 -2006. The data are a representative sample of the non-
institutionalized population. The sample was selected based on a multistage, stratifi d 
sampling design (270). Due to differential probabilities of participants’ selection, 
sampling weights adjusting for non-response and post stratification were provided. A 
total of 4044 subjects (men and women) ≥ 20 years of age, who were interviewed and 
underwent medical examination, were included in this study.  The exclusion criteria 
included being pregnant, lactating, using insulin, having cancer and missing values. 
In order to estimate the prevalence of MetS, only 1445 participants with complete 
data on NCEP/ATPIII criteria were considered. Detailed information on NHANES 
dataset design specifications, consent documents, institutional review board approval 




The NHANES data included socio-demographic, lifestyle, anthropometrics 
measurements, dietary intake, medical information, clinical histories, phyical 
examination, blood serum nutrient and biochemical lab values. Demographic and 
socioeconomic status data, such us poverty income ratio, education (< high school, 
high school graduate, > high school), marital status and having health insurance were 
collected using a questionnaire. An electronic scale and a fixed stadiometer were used 
to measure the weight and height of participants. Dietary intake, based on a 24 hour 
food intake recall, was collected to estimate intakes of energy, nutrients and other 
food components. Dietary variables including total Kcal, fat, carbohydrate, protin, 
fiber, vitamin C, Carotene, vitamin E, selenium, and Iron were estimated using 
USDA’s Food and Nutrient Database for Dietary Studies 3.0 (FNDDS 3.0). Serum 
concentrations of vitamin C, Carotene, Vitamin E, selenium and iron nutrients were 
also measured.  
The metabolic syndrome was defined comparing the 2009 Joint Scientific 
Statement for NCEP and IDF and a modified NCEP/ATP III definition to rec gnize 
the prevalence of MetS as influenced by the measures of obesity. WC was measured 
at the high point of the iliac crest to the nearest 0.1 cm during minimal respiration.  
Up to three blood pressures were recorded using a standard mercury 
sphygmomanometer.  For subjects with three readings, the last two measurements 
were averaged; for only two reading, the last measurement was taken; and in the case 
of one reading, that single measurement was considered. Glucose was measured using 
an hexokinase enzymatic reaction. Serum triglycerides were determined 
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enzymatically after hydrolyzation to glycerol. HDL-cholesterol was quantified using 
heparin-manganese chloride mixture.  
The diagnosis of MetS was determined for each participant as the presence of 
at least three of the components of MetS based on three definitions presented in 
Table 13.  Participants who reported currently using antihypertensive, antidiabetic, or 
medications to control triglycerides and cholesterol levels were considered to be 
positive for MetS (IDF and NCEP/ ATPIII (29). The cut off values used were similar 
across methods except for WC.  Three categories of high waist circumference w re 
defined as ≥102 cm (40 inches) in men and ≥88 (35 inches) from NCEP/ATPIII, ≥96 
cm (38 inches) in men and ≥99 (39 inches) from our previous study, and the IDF 
values of ≥ 94 cm in men and ≥ 80 cm in women. 
The variables selected to assess some of the characteristics associated with 
having MetS include urinary albumin measured by a solid-phase fluorescent 
immunoassay, serum C - reactive protein measured using latex-enhanced 
nephelometry, plasma levels of fibrinogen determined by the Clauss clotting method 
using the STA-Compact. Serum alkaline phosphatase was measured using Ostase 
Immuno Enzymetric Assay (272). Additionally, concentrations of plasma liver 
function tests alanine aminotransferase, alkaline phosphatase, gamma-glutamyl 
transferase, and uric acid (273) were considered during the analysis. Other covariates 
of interest included age, gender, PIR, marital status, and having medical insurance. 
Detailed descriptions of data collection and analysis methods for NHANES have been 




Definition of variables  
For adults 20 years and older, the level of education completed was categorized as 
less than 9th grade education, 9-11th grade, high school/GED, some college or 
associates degree, and college graduate or higher (274). The marital status vari ble
was defined as married, widowed, divorced, separated, never married, and living with 
a partner. Poverty income ratio (PIR) values below 1.00 are below the official poverty 
threshold, whereas PIR values of 1.00 or greater indicate income above the poverty 
level. The health insurance coverage was defined as being covered by health 
insurance or some other type of health care plan including governmental programs. 
Physical activity variable described participants usual daily activities of a typical day. 
The categories included sitting mainly without much walking, standing or walking a 
lot without lifting objects, lifting light load or climbing stairs or hills often, and heavy 
work or carrying heavy loads (275).  
C-reactive protein (CRP) was determined and classified based on existig 
classification of the American Heart Association.  A CRP <1.0 mg/L indicates low 
risk of developing cardiovascular disease,  the levels between 1.0 and 3.0 mg/dL is 
indicative of at average risk for cardiovascular disease, and higher than 3.0 mg/dL 




Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, 
North Carolina) and STATA 11 data analysis and statistical software programs 
(StataCorp LP, College Station, TX). Descriptive analyses were carried out separately 
in men and women. Data were summarized and displayed as mean and standard error 
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(SE) for continuous variables and as percentage for categorical variables. T- t ts and 
χ
2 were used for comparisons between men and women, and for comparisons of 
subjects with or without MetS. Age adjusted prevalence rates of MetS was calculated 
to eliminate the confounding effect of age. Age standardization was performed by the 
direct method using the projected year 2000 US population by NHANES (190). 
Logistic regression was used to assess the impact of multiple independent variables, 
presented simultaneously, on the presence/ absence of MetS status. For each type of 
analysis, statistical significance was considered at P < 0.05. 
 
Results 
In the study, African American women who have MetS were on average 
older, had higher BMI and WC compared to men and those who do not have MetS as  
shown in Table 14.  Within the African American men group, individuals with MetS 
were also older and had higher BMI &WC than men without MetS. Distribution of 
age-specific BMI (Figure 8 and 9) revealed consistent high BMI among participants 
with MetS for both gender. There was a statistically significant (p<0.05) association 
between PIR and MetS status among men. A high proportion of men with No MetS 
had a lower PIR, while subjects with a higher PIR showed an increase MetS status. 
Although education was independent of MetS status, it was observed that men and 
women with lower education level had a higher percentage of MetS syndrome. Others 
with higher education had a lower MetS syndrome. For marital status, subjects who 
had never married had the lowest percentage of MetS while a higher proportion was 
observed among married men. Among men and women, individuals with health 
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insurance showed a high proportion of MetS. In terms of lifestyle for both men and 
women, those who indicated a lower daily average level of physical activity showed 
higher MetS than the most active. Alcohol intake in both genders did not show any 
significant correlation with MetS status. Women and men who never smoked had a 
higher MetS syndrome. 
It is noticed in Table 15 that an assessment of total calorie, fat, protein and 
carbohydrate intake revealed a higher geo-mean among no MetS than individuals 
with MetS among men and women. Age specific showed similar findings in addition 
to a decreased in calorie and macronutrient intake with increasing age. Total protein, 
carbohydrate, fat intake and fiber intake were higher in men compared to women. 
Men without MetS significantly consumed higher levels of total carbohydrate, while 
in women total protein and fat were significantly elevated in no MetS. This 
observation was reversed within certain age categories. Men with MetS in the 30-39 
and 40-49 age groups consumed higher levels of calories, carbohydrate, and total fat 
compared to those without MetS. In women, higher intake of total kcal was observed 
in the 40-49 year of age group, and high fat consumption was recorded in the 30-39 
and 40-49 age categories. Micronutrients intake including vitamin C, carotene, 
vitamin E, selenium and iron were lower in MetS compared to individuals without 
MetS. Only the findings for vitamin E, Selenium and Iron were statistically 
significant in women. In examining the serum nutrient levels, estimates wer omitted 
for men due to inadequate number of subpopulation members. Among women, except 
vitamin E, vitamin C, and carotene, iron consumption was statistically significantly 
lower among those with MetS.  
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The evaluation of selected laboratory components is summarized in Table 15. 
Hepatic tests show higher laboratory values in men and women with MetS compared 
to no MetS condition. The differences for ALT, ALP and GGT by MetS status were 
significant among women, while for men, only the statistically significance was 
observed for ALP. Other laboratory tests including CRP, fibrinogen, uric acid and 
microalbuminuria were significantly higher in MetS vs. non MetS respondents in both 
gender. 
Table 16 summarizes age- adjusted prevalence of metabolic syndrome, which 
was 30.9% for men and 30.3% for women when the threshold of ≥ 95cm for men and 
≥98 cm for women were used. The prevalence was slightly lower in women 
compared to men. The prevalence using the IDF threshold of ≥80 cm was much 
higher in women. There was no difference in the unadjusted data for men and women 
using a WC standard of ≥95cm/98cm and ≥94cm/80cm thresholds. However using 
the WC threshold of ≥102/88 cm, women had higher MetS prevalence of 34.1% and 
it was lower in men 23.5%. Considering prevalence by age categories, it increased 
with age ranges and reached a peak at 60-69 years of age for both gender. Elderly 
men (70+ years) had similar MetS prevalence of 46.4% when using the ≥ 95/98 cm 
and the IDF thresholds of ≥ 94/80 cm.  A lower prevalence of 39.2% was observed in 
the same group when using NCEP/ATPIII thresholds of ≥102/88 cm. Among women, 
MetS was higher across age categories when using NCEP/ATPIII thresholds of ≥88 
cm and IDF cut-offs of ≥80 cm.   
 Lastly, logistic regression was run for the analysis and prediction of the 
dichotomous outcome of whether individuals would be classified as having metabolic 
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syndrome or not. The research hypothesis posed was that the likelihood that 
individual have MetS is related to presence of biochemical, lifestyle, and dietary 
predictors. The results showed that according to the model, the log of the odds 
(coefficients) of having MetS was significantly and negatively related to 
divorced/separated marital status; stopped smoking; high percent of calorie from 
carbohydrate and protein; high vitamin E, and Iron intake ( P <0.05; Table 17).  
These specified values were associated with the less likelihood of respondents having 
MetS holding other variables constant. The predictors for which respondents were 
more likely to have MetS include age, decreased physical activity, high levels of uric 
acid, and high intake of selenium.  
 
Discussion 
This study used the current definition of MetS and suggested WC thresholds to 
estimate the current metabolic syndrome status among African American adults. The 
prevalence of metabolic syndrome is higher (30.9%) in men than previously 
estimated (25.5%) (269) when the criteria for abdominal obesity of  ≥ 102 cm was 
used. This WC value was 7 cm higher than our estimated appropriate WC of 95 cm, 
thus may not capture participants presenting with other metabolic components (276). 
Our findings also show that the prevalence of MetS in men remains lower than the 
average national rate of 34.3% (269, 277), which increased from 23.7%, the estimate 
derived from using the 1988-1994 NHANES III data (72). The prevalence rate from 
our study 30.9% gave results close to a recent estimate of 32.5% for the MetS using 
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the IDF WC values of ≥ 94 cm. The observed increase of 1.6% was expected as the 
IDR threshold for WC is smaller.  
 In women, our observed prevalence of 30.3% was lower than the national average of 
32.4% and 38.2% estimated using the ≥ 88 cm threshold).  Our study suggests the use 
of a WC of 98 cm, which we determined independently of BMI status and was based 
on the presence of at least 2 out of the 4 other MetS criteria. 
 Waist circumference has been shown to be a better criterion in assessing 
metabolic risk factors than BMI (72) and is the most prevalent component of MetS. 
The findings in this study support the need for using a WC cutoff point that is not 
estimated from existing BMI of overweight or obesity values (2).  There is still a need 
for a consensus about which WC threshold to use in the USA. The recent harmonized 
definition suggests the use of 102 cm for men and 88 cm for women (29), while the 
2005 American Heart Association/National Heart, Lung and Blood Institute 
recommends use of ethnic specific thresholds.  
 Despite the research and public interest in MetS, the definition and prevalence 
estimates remain unclear for certain population groups, which may be one of the 
contributing factors to the low use of metabolic syndrome by health care providers in 
the diagnosis of the syndrome (278). In order to bridge the gap between the 
deteriorating health status of the population and tools needed for screening and 
preventing chronic diseases, further research is needed to advance the 
conceptualization and formulation of group specific thresholds for different 
population groups. Among African Americans, the triglycerides and HDL cholesterol 
levels still require determination of thresholds that are specific to this group and these 
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may also affect the current estimates of MetS prevalence. Considering that in his 
study a large percent (83%) of participants with  MetS have health insurance, a clear
definition of MetS can enhance the diagnosis of this condition in order to implement 
therapeutic lifestyles and treatments that would improve the health status and reverse 
the high rate of death related to heart disease and diabetes (2,267).  
 Our findings of the demographic, anthropometrics, biochemical, and lifestyle 
characteristics of individuals who have MetS are consistent with previous studies 
(269). Older age, low education, decreased physical activity, hepatic test 
abnormalities, chronic inflammatory indicators, microalbuminuria, high uric acid and 
high fibrinogen status are abnormalities found among individuals with MetS 
compared to those without MetS. This underscores the need for effective assessment 
and health care plans to treat the syndrome. However, our logistic regression results 
only showed age, low physical activity, and uric acid level as significant predictors of 
positive MetS status. The inclusion of high selenium consumption among the 
predictors of MetS cannot be explained by this study and require further 
investigation.  In general, higher intake of micronutrients and increased physical 
activity were confirmed to predict the non-MetS status.  However, dietary 
information provided unreliable results on the lower consumption of macronutrients 
by individual with MetS. This could be related to the underestimation of food intake 
by subjects with MetS and use of 24 hour recalls which might not represent an 






In summary, our results indicate that the prevalence of metabolic syndrome among 
African American men is higher than current rates when the WC (95cm) that predicts 
the presence of MetS criteria was used.  It was observed that 5.4% of individuals with 
MetS cannot be diagnosed with this condition when the NCEP-ATPIII WC of 102 cm 
is considered. Among women, the prevalence of MetS slightly decreased but 
remained high (~31%) when a WC of 98 cm was applied.  The current NCEP-ATPIII 
WC of 88 cm in women is too low and captures a percentage of subjects without 
MetS. The use of WC determined based on presence of multiple metabolic risk 
factors provides a better assessment of MetS than WC based on BMI.  The stunning 
increase in the MetS prevalence in the USA and among various ethnic groups coupled 
with the increase in obesity (269) calls for population specific assessment crit ria and 


















Table 13.  Diagnostic criteria of the metabolic syndrome 
  - 
 






3 or >  
Components 
3 or >  
Components 
3 or >  
Components 
Waist circumference    
Men (cm) ≥ 102 ≥ 95 ≥ 94 
Women (cm) ≥ 88 ≥ 99 ≥ 80 
HDL  Cholesterol 
mg/Dl 
   
Men < 40 < 40 < 40 
Women < 50 ≥ 50 ≥ 50 
Blood Pressure  
mmHg 
≥ 130/85 ≥ 130/85 ≥ 130/85 
Glucose (mg/dL) ≥ 100 ≥ 100 ≥ 100 
Triglycerides 
(mg/dL) 
≥ 150  ≥ 150 ≥ 150 
ATPIII- Diagnostic Criteria of the Adult Treatment Panel III Revised by the American Heart Association and the National Heart, 
Lung, and Blood Institute; Modified ATPIII* - Diagnostic Criteria of the Adult Treatment Panel III Revised by the American 
Heart Association and the National Heart, Lung, and Blood Institute –WC adjusted to 95 cm for men and 99 cm for women; IDF 














Figure 8 .  Age Specific BMI Index by MetS-African American Adult Men-
NHANES 1999-2006 
 
Values: distribution of age group specific BMI;  BMI: body mass index; No MetS: no metabolic 








Values: distribution of age specific BMI; BMI: body mass index; MetS: presence of 3 or > metabolic 








Table 14.  Characteristics of African Americans Adults by Metabolic Syndrome 
Status, NHANES 1999-2006 
 
Men                  Women   
No MetS MetS   No MetS MetS   
N Mean (SE) N Mean (SE) 
p  
value 
N Mean (SE) n Mean (SE) 
p 
value 
Age ( years) 431 39.0 (0.58) 213 50.2 (0.93)   469 41.0 (0.71) 216 51.3 (1.1) 
BMI (kg/m²) 419 26.4 (0.29) 209 32.0 (0.37)   457 29.6 (0.32) 214 36.7 (0.49)   
Waist (cm) 410 91.0 (0.77) 205 109.5 (0.92)   440 94.0 (0.69) 213 112.3 (0.78) 
PIR < 1.85 179 40.9(2.4) 80 34.2(3.5) 0.045  240 51.1(1.8) 103 46.9(3.8) 0.057 
1.85 - ≤3.5 137 31.4(1.9) 62 29.4(3.9)   105 22.1(1.8) 67 31.4(3.1) 
> 3.5 122 27.7(2.1) 73 36.4(3.3)   121 26.7(2.0) 46 21.6(3.8) 
Education 0.93 0.13 
< 12 years 160 32.1(2.7) 87 34.1(4.0) 137 24.5(2.2) 83 32.8(3.4) 
= 12yr/GED  113 25.3(2.0) 54 24.3(2.8)   112 22.6(1.9) 62 23.9(3.1) 
Some college 137 30.2(2.1) 61 28.4(3.2)   180 36.0(2.3) 69 30.8(3.7) 
Graduate+ 59 12.4(1.7) 28 13.1(2.6)   83 16.8(2.0) 28 12.4(2.3) 
Marital Status <0.001 <0.001 
Married 172 36.5(2.7) 123 51.1(3.3)   146 29.4(2.1) 78 32.7(2.9) 
Widowed 23 2.7(0.4) 21 7.0(1.7)   47 6.8(1.0) 53 17.9(2.5) 
divorced/separated 52 10.5(1.4) 31 14.2(2.2)   117 23.2(1.6) 61 26.2(3.2) 
with partner 164 38.9(2.7) 32 15.5(2.6)   147 30.9(2.1) 35 17.6(2.9) 
never married 45 11.2(1.6) 22 12.1(2.3)   46 9.6(1.4) 11 5.5(1.6) 
Health Insurance 
Yes 323 67.4(2.7) 195 83.1(2.4) <0.001 405 79.5(2.4) 202 84.1(2.9) 0.188 
No 139 32.6(2.7) 34 16.9(2.4)   102 20.5(2.4) 38 15.8(2.9) 
Physical Activity <0.001 0.072 
mainly seats 94 18.2(1.6) 76 29.1(2.4)   140 26.6(1.8) 92 37.5(3.9) 
stand or walk 234 49.9(2.4) 118 53.9(3.1)   297 57.6(2.4) 121 49.6(3.9) 
light load, stairs, 
hills 96 21.3(1.9) 24 11.1(2.2)   64 12.6(1.8) 22 9.9(2.1) 
heavy load 46 10.5(2.1) 10 5.8(1.9)   14 3.1(1.0) 7 2.9(1.3) 
Alcohol Intake 0.07 0.512 
<30 drinks/month 303 84.4(2.2) 156 91.1(2.3)   405 95.6(0.9) 193 96.1(1.4) 
≥ 30 - ≤ 60 /month 34 10.8(1.8) 11 7.7(2.2)   12 2.9(0.9) 4 1.6(0.9) 
≥ 61 drinks/month 16 4.7(1.2) 2 1.2(0.8)   6 1.4(0.4) 3 2.3(1.4) 
Cigarette Smoking <0.001 0.037 
Daily 163 35.5(2.6) 63 28.6(3.3)   94 18.4(1.8) 46 21.7(3.0) 
Stopped 73 12.7(1.2) 66 23.3(2.6)   65 11.7(1.4) 52 17.8(2.3) 
Never 233 51.8(2.6) 108 48.1(3.5)   354 69.9(2.6) 144 60.5(3.2) 
Mean (SE) : mean and standard error; No MetS = absence of metabolic syndrome ;  MetS= Presence of 3 or > 







Table 15.  Comparison of dietary intake, nutrient serum levels and biochemical 
characteristics by metabolic syndrome status among African American Adults, 
NHANES 1999-2006* 
  Men   Women 
  No MetS   MetS  
  No MetS   MetS  
Dietary N Mean (SE) N Mean (SE) pvalue N Mean (SE) N Mean (SE) Pvalue 
Total Kcal 207 2347 (61.3) 406 2079 (65.3) 0.001 214 1706 (39.4) 437 1553 (43.6) 0.023 
Total Prot. (gm) 207 82 (2.6) 406 78 (2.5) 0.109 214 61 (1.7) 437 56 (1.7) 0.044 
Total CHO 
(gm) 
207 276 (7.1) 406 242 (8.6) 0.001 214 205 (5.4) 437 194 (5.6) 0.203 
Total Fat (gm) 207 80 (2.9) 405 76 (3.1) 0.191 214 62 (1.4) 437 55 (2.1) 0.005 
Fiber (gm) 207 11.3 (0.9) 406 8.9 (1.3) 0.09 214 8.9 (0.4) 437 8.4 (0.6) 0.524 
Vitamin C (mg) 207 65.9 (11.3) 402 44.4 (11.6) 0.197 214 39.3 (4.8) 437 53.2 (10.3) 0.249 
Carotene (RE) 31 139.2 (31.6) 57 79.2 (32.8) 0.141 37 130.2 (16.9) 84 162.1 (37.7) 0.418 
Vitamin E (mg) 207 7.5 (0.8) 405 6.1 (0.6) 0.09 214 6.6 (0.3) 437 5.3 (0.4) 0.014 
Selenium (mcg) 207 114.1 (5.7) 406 117.3 (6.9) 0.736 214 98.9 (4.1) 437 67.8 (4.5) 0.000 




124 (-) 239 (-) (-) 120 0.87 (0.02) 250 0.61 (0.05) 0.001 
Carotene ug/dL 178 (-) 360 (-) (-) 176 2.4 (0.19) 370 1.5 (0.17) 0.004 
Vitamin E 
ug/dL 
211 (-) 422 (-) (-) 213 996.8 (17.1) 455 997.1 (38.8) 0.997 







Biochemical Laboratory Characteristics by Metabolic Syndrome Status  among African American adults , 
NHANES  1999-2006* 
    Men   Women 
    No MetS   MetS  
  No MetS   MetS   
HEPATIC 
TEST n Mean (SE) N Mean (SE) Pvalue n Mean (SE) n Mean (SE) Pvalue 
ALT (U/L) 210 27. 3 (0.9) 421 28.2 (1.0) 0.502 213 18.9 (0.6) 452 21.3 (0.8) 0.015 
ALP (U/L) 177 66.5 (1.2) 360 72.7 (1.9) 0.01 176 67.8 (1.4) 367 76.1 (1.7) 0.001 
GGT (U/L) 210 37.3 (3.03) 422 41.5 (3.4) 0.341 213 22.7 (1.1) 452 33.1 (3.3) 0.004 
OTHERS 
CRP (mg/dL) 211 0.13(0.01) 426 0.29 (0.03) 0.001 214 0.23 (0.02) 462 0.62 (0.05) 0.001 
Fibr. mg/dL 70 361.7 (9.3) 104 396.3 (12.2) 0.03 73 386.8 (7.4) 123 439.7 (11.9) 0.002 
uric acid  
mg/dL 
210 6.1 (0.16) 422 7.0 (0.21) 
0.001 
213 4.8 (0.15) 452 5.7 (0.14) 
0.001 
Micralb. mg/dL 209 10.3 (0.6) 423 18. 6 (2.0) 0.001 215 10.8 (0.5) 452 18.6 (1.9) 0.001 
Means - geo-mean & standard error;  ALT - Alanine aminotransferase ALT (U/L) ; ALP Alkaline phosphatase (U/L); GGT (U/L); CRP C-reactive 
protein(mg/dL); Fibr. Fibrinogen;  Micralb. Microalbuminuria(mg/L) *p value based on log results. 
Means - geo-mean & standard error. Total Kcal Energy (kcal); Total Prot.: Total Protein (gm); total CHO: carbohydrate (gm); Total fat (gm); 
 *p value based on log results. (-) omitted due to inadequate number of subpopulation members. 
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Table 16.  Age -adjusted and age-specific prevalence of metabolic syndrome 
among African Americans adults, NHANES 1999-2006 
 
  










Adjusted 1457 11111 30.6 (1.2) 11111 31.5 (1.1) 11111 35.2 (0.9) 
Men 700  30.9 (1.8)  25.8 (1.7)  31.1 (1.7) 
Women 757  30.3 (1.3)  35.9 (1.2)  38.3 (1.1) 
Unadjusted 1329 28.3 (0.6) 29.3 (1.1) 28.7 (1.1) 
Men 644 28.4 (1.9) 23.5  (1.8) 28.6 (1.9) 
Women 685 28.8 (1.4) 34.1 (1.5) 28.8 (1.3) 
Men  
20-29 126 8.6 (2.2) 5.3 (1.9) 8.6 (2.2 
30-39 126 21.9 ( 3.8) 19.6 ( 3.4) 21.9 (3.8) 
40-49 137 29.1 (3.8) 23.7 (3.5) 29.9 ( 3.7) 
50-59 65 43.7 (5.3) 35.5 (5.0) 43.7 (5.3) 
60-69 110 60.5 (3.8) 52.6 (4.1) 60.5 (3.8) 
70+ 80 46.4 (4.1) 39.2 (4.7) 46.4 (4.1) 
 Women  
20-29 114 10.2 ( 2.8) 12.4 (3.3) 14.5 (3.2) 
30-39 131 19.8 (3.4) 20.8 (3.2) 20.8 (3.2) 
40-49 160 28.8 (4.1) 36.5 (4.1) 40.4 (4.2) 
50-59 85 38.7 (5.2) 51.9 (5.2) 51.9 (5.3) 
60-69 110 59.7 (3.6) 60.4 (3.6) 64.7 (3.4) 
70+ 85   43.4 (5.2)   51.9 (5.5)   54.5 (5.0) 
* MetS- Metabolic Syndrome defined using Waist Circumference (WC) ≥ 95cm in men and ≥ 98 cm in women 
** MetS- Metabolic Syndrome defined using WC ≥102 cm in men and ≥ 88 cm in women  (NCEP/ATP) 















Table 17.  Predictors of metabolic syndrome status by selected factors among 
African American adults, NHANES 1999-2006 






    
Intercept   1 -24.1426 3.7234 42.0425 <.0001 
Age 60 + yrs 1 2.1953 0.7721 8.0833 0.0045 
physical 
activity 
seat 1 16.0856 2.3241 47.9025 <.0001 
  stairs, hill light load 1 14.1954 3.0035 22.3379 <.0001 
  Walk stand 1 13.7886 2.3165 35.431 <.0001 
Marital 
status 
divorced separated 1 -1.5027 0.6159 5.9524 0.0147 
  never married 1 0.7731 1.3116 0.3474 0.5556 
  Partner 1 -0.2395 1.6663 0.0207 0.8857 
  Widowed 1 0.746 0.8449 0.7796 0.3773 
smoking daily/ sometimes 1 -0.7349 1.2137 0.3666 0.5448 
  Stopped 1 -2.5249 0.4944 26.0849 <.0001 
PCALCHO percent of CHO 1 -0.0305 0.0165 3.4275 0.0641 
PCALPROT percent of Prot 1 -0.2427 0.0742 10.7081 0.0011 
LBXSUA Uric acid 1 0.599 0.2435 6.0496 0.0139 
LOGVITE log vit E 1 -0.8379 0.4268 3.8549 0.0496 
LOGSEL log sel 1 3.2573 1.1398 8.1668 0.0043 
LOGIRN Log Iron 1 -1.3628 0.6666 4.1803 0.0409 
Pcalcho = percent of calories from carbohydrate; Pcalprot: percent of calories from protein;  





















Chapter 5:  SUMMARY AND IMPLICATIONS 
The study examined the waist circumference and body mass index cut-offs for 
African Americans according to the clustering of metabolic syndrome risk factors. 
It also assessed the prevalence of MetS as influenced by measures of obesity and 
correlates of the syndrome. Using NHANES 1999-2006 data, the major findings 
suggest that current NCEP/ATP III waist circumference of 102 cm fails to dentify 
individuals with multiple metabolic risk factors among males, while for femal , the 
88 cm threshold include individuals without MetS resulting in the estimation of a 
high prevalence of MetS in women.  The thresholds with relative high sensitivity and 
specificity are 95 cm in men and 98 cm in women. Findings on the relationship 
between BMI and metabolic health risk factors, that accompany excess adipo ity, 
show that African American females experience health issues at high BMI 32kg/m² 
compared to males at 28kg/m². Corresponding waist circumference values using 
simple linear regression or ROC analysis were 96 cm and 99 cm, respectively, for 
males and females. Thus the findings support the need to review existing WC cut off 
values. The evaluation of MetS prevalence using the newly estimated WC values 
revealed a higher age-adjusted MetS prevalence of 30.9% than current estimated of 
25.5% and a decrease in MetS rate among women (30.3%) compared to the national 
average of 32.4% among women.  
Implications 
African American females have high obesity rates compared to men. In general,  
MetS prevalence and obesity continue to rise in the USA. With increase health costs, 
reduced quality of life, and the need to lower health disparities, successful prevention 
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and management of increasing metabolic abnormalities and related cardiovascular 
and type 2 diabetes illnesses require accurate identification of high-risk ind viduals. 
Defining population based MetS criteria will enhance its diagnosis, as well as the 
prevention and control of non-communicable diseases. This implies using simplified 
screening tools to identify high risk individuals that would yield effective intrvention 
and costs. Within the African American population group, further research is still 
needed to conceptualize this MetS. This would provide appropriate cut off values for 
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